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PGTandMe:
SOCIAL NETWORKING-BASED
GENETIC TESTING AND THE
EVOLVING RESEARCH MODEL
Valerie Gutmann Koch†

ABSTRACT
The opportunity to use extensive genetic data, personal information,
and family medical history for research purposes may be naturally
appealing to the personal genetic testing (PGT) industry, which is
already coupling direct-to-consumer (DTC) products with social networking technologies, as well as to potential industry or institutional
partners. This article evaluates the transformation in research that the
hybrid of PGT and social networking will bring about, and—
highlighting the challenges associated with a new paradigm of “patient-driven” genomic research—focuses on the consequences of
shifting the structure, locus, timing, and scope of research through
genetic crowd-sourcing. This article also explores potential ethical,
legal,
and
regulatory
issues
that
arise
from
the
hybrid between personal genomic research and online social networking, particularly regarding informed consent, institutional review
board (IRB) oversight, and ownership/intellectual property (IP) considerations.
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INTRODUCTION: BLOOD, SWEAT, TEARS . . . AND SPIT
Lorenzo Odone’s struggle with adrenoleukodystrophy (ALD), a
rare incurable genetic disorder that results in brain damage, failure of
the adrenal glands and, eventually, death, was memorialized in the
Oscar-nominated film Lorenzo’s Oil. The 1992 movie tells the story
of Lorenzo’s parents’ mission to find a cure on their own, after failing
to find a doctor who could treat their son’s illness.1 They reviewed
studies and experiments, questioned doctors, organized an international symposium about ALD, and sought out a chemist to distill the
oil that, in the movie, stopped the progression of Lorenzo’s disease.
The moral of the story is that if the medical world fails to help us, we
must help ourselves, even if it means contributing our own blood,
sweat, and tears to find the treatments or cures we seek.
Today, genetic technology holds the promise of better and more
frequent treatments and cures. It is also being used for more recreational purposes—allowing customers to glean personal health and
ancestral data for informational and nonmedical reasons. Most per1

LORENZO’S OIL (1992); Roger Ebert, Lorenzo’s Oil, ROGEREBERT.COM
(Jan.
15,
1993),
http://rogerebert.suntimes.com/apps/pbcs.dll/article?AID=/19930115/REVIEWS/301
150303/1023.
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sonal genome testing (PGT) kits require the consumer to send in a
DNA sample—often a spit sample or cheek swab—which is analyzed
by a U.S. government-certified laboratory.2 The company then notifies the consumer of the results by telephone, mail, or, more recently,
online. Now that some PGT companies have coupled their direct-toconsumer (DTC) products with social networking technologies,3 consumers can communicate and share their information—including extensive personal information, genetic data, and family history—with
others.
The opportunity to use such a wealth of information for research
purposes is naturally appealing to the PGT companies and their potential industry or institutional partners. Sourcing research participants
from social networking sites is often referred to as “crowd-sourcing”
or “open-source research.” PGT companies such as 23andMe have
heralded the advantages of what they refer to as the “democratization
of research,” or “patient-driven research.”4 Often referred to as “collaborative,” consumers/participants are purportedly involved in choosing the focus of the research and contributing their own genetic and
personal data.
Genomic research arising out of PGT and social networking could
produce a number of transformations in the model for clinical research. Recruitment and enrollment problems could be lessened as
patient pools become larger and more diverse. Data shortages or gaps
could be eliminated as participants could share every aspect of their
personal and genetic information. Doubts about the validity of the
results and uncertainty about conclusions could be reduced, as investigators could more easily reproduce each others’ research.5 The
combination of DTC genomic testing services with online social networking promises the advancement of research across entire populations as well as for personalized medicine, or pharmacogenomics,

2
See CTRS. MEDICARE & MEDICAID SERVS., Clinical Laboratory Improvement Amendments (CLIA), http://www.cms.gov/CLIA/ (last updated July 12, 2011).
3
Generally, online social networking involves sharing and communicating
information over the internet. Online communities provide a forum for people with
similar interests, activities, or goals.
4
See, e.g., Rob Waters, Google-Backed 23andMe Seeks Parkinson’s Patients Spit (Update 1), BLOOMBERG (Mar. 12, 2009) (quoting Ann Wojcicki, who
stated, “We also believe we are really democratizing research in a new way.”),
http://www.bloomberg.com/apps/news?pid=newsarchive&refer=home&sid=akLbmqi
B1lSw.
5
One early example of patient-driven medical advances using social networking technology is Flu Wiki, which is used to generate epidemiological maps of
illness outbreaks. FLUWIKI, http://www.fluwiki.info/ (last visited Sept. 17, 2009).
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shifting both the focus and locus of research and revealing challenges
that are not addressed by our current regulatory framework.
This article focuses on the potential ethical, legal, and regulatory
issues that arise from bringing together personal genomic research and
online social networking, and highlights the challenges associated
with a new paradigm of “patient-driven” genomic research. Part II
includes a summary of the PGT/social networking products currently
on the market—with respect to both the testing services available and
the companies’ intentions to use data for research purposes. Part III
considers the evolving PGT/social networking hybrid for clinical research. Part IV discusses the implications of social networking-based
genetic research in terms of shifting the structure, locus, timing, and
scope of human subjects research. Part V explores the implications
this evolving research model may have on a number of ethical, legal,
and policy dimensions related to informed consent and institutional
review board (IRB) oversight. Finally, Part VI addresses ownership
and intellectual property (IP) considerations for the contributions or
products of the techno-social hybrid of PGT and social networking.
I.

PERSONAL GENOMIC TESTING: WHAT’S ON THE
MARKET NOW?

The market for PGT continues to expand, with a test to match the
needs of almost any consumer. There are services that provide genealogical information to fill in a family tree (e.g., deCODE Genetics or
23andMe) and tests focused on disease and trait prediction (e.g.,
23andMe, Navigenics, Pathway Genomics, or Interleukin Genetics).
There are tests based on single-nucleotide polymorphisms (SNPs) or
specific genetic markers (e.g., 23andMe, Navigenics, or Pathway Genomics), and tests that conduct genome-wide scans (e.g., Knome).
There are options for individuals who are concerned with privacy
(e.g., Knome) as well as for those who want the opportunity to share
and discuss their test results with others (e.g., 23andMe). Some companies require customers to sign “informed consent” forms prior to
purchasing a service or participating in genetic research while others
do not. Some disclose the potential use of the data gleaned from their
websites in future research—either by internal investigators or by
those who have purchased rights to the databases of information—
while others currently have no intent to conduct any research at all.
Each company’s offerings vary by price, services, and policies, and
new companies and products seem to enter the market daily. Although Interleukin Genetics, Knome, Navigenics, deCODE Genetics,
Pathway Genomics, TruGenetics, and 23andMe all provide some form
of PGT service, not all of them intend to pursue research agendas util-
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izing the information to identify tests, diagnostics, or treatments.
However, the collection of genomic data, often coupled with other
personal information, renders a discussion of their services and policies useful.
Knome (pronounced “know me”) is a private PGT company that
interprets human genomes for pharmaceutical and clinical researchers.6 The company, founded in 2007, was the first of its kind to commercially offer complete genomic sequencing. To meet the needs of
the research community, Knome established KnomeDISCOVERY to
deliver data and analysis for complete human genome and exome sequencing.7 Unlike some of the other companies that offer social networking opportunities, Knome has emphasized privacy.8
deCODE Genetics’ service provides disease-specific genetic tests,
as well as a genealogy service.9 deCODE Genetics’ services include a
full forty-seven disease and trait scan (including ancestry information), a “Cardio” scan, and a “Cancer” scan.10 The conditions covered
by deCODE Genetics’ complete scan, which captures over a million
SNPs, include breast cancer, risk of heart attack, obesity, psoriasis,
Alzheimer’s disease, asthma, eye color, and restless leg syndrome.11
Results of the genetic analysis, performed in deCODE Genetics’ labo6
FAQs, KNOME, http://knome.com/company/faqs/ (last visited Apr. 12,
2011). In July 2011, scientists used Knome’s services to aid in the discovery of a
mutation associated with an inherited form of Parkinson’s disease. Carles VilariñoGüell et al., VPS35 Mutations in Parkinson Disease, 89 AM. J. HUMAN GENETICS 162,
162 (2011).
7
KnomeDiscovery, KNOME, http://knome.com/solutions/knomediscovery/
(last visited Oct. 24, 2011).
8
David P. Hamilton, The Nitty-Gritty on Knome: How it Works,
VENTUREBEAT (Nov. 29, 2007), http://venturebeat.com/2007/11/29/the-nitty-grittyon-knome-how-it-works/. Formerly, the FAQs section of the Knome website explained that consumers will own their genomic information, and that they are under
no obligation to continue using the company’s services or to maintain their genome
with
Knome.
FAQs,
KNOME,
http://web.archive.org/web/20091129101404/http://www.knome.com/about/faqs.html
(last visited Sept. 17, 2009) (accessed by searching for the URL on Internet Archive
database).
9
DECODEME, http://www.decodeme.com/ (last visited Apr. 12, 2011).
deCODE is an Icelandic company that endeavored to set up an Icelandic Health Sector Database (HSD) containing the medical records and genealogical and genetic data
of all Icelanders. David E. Winickoff, Genome and Nation: Iceland’s Health Sector
Database and its Legacy, INNOVATIONS, Spring 2006, at 80, 80.
10
deCODEme
Complete
Scan,
DECODEME
(June 8,
2011),
http://www.decodeme.com/complete-genetic-scan; deCODEme Cancer Scan,
DECODEME (Feb. 8, 2010), http://www.decodeme.com/cancer-scan; deCODEme
Cardio Scan, DECODEME (Feb. 8, 2010), http://www.decodeme.com/cardio-sca
11
Conditions
We
Cover,
DECODEME,
http://www.decodeme.com/conditions-covered (last updated Feb. 18, 2010).
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ratory in Reykjavik, Iceland, are made available through a genome
browser tool that gives users access to the variant information on the
SNPs analyzed in the scan. The company also offers genetic counseling through a network of certified genetic counselors, but does not
require counseling prior to or after using its services. The company
states that, as the account owner, the consumer owns the genetic data
within the deCODE Genetics account, and he or she can choose to
make the information private or public to all users or only to a list of
selected “friends.”12 deCODE may also contact users to invite them
to participate in research studies.13 In fact, the CEO of deCODE, Kari
Stefansson, has stated that the company has conducted studies involving more than 10,000 people with the same disease.14 deCODE Genetics also maintains a blog, heralding discoveries by the company
and announcing the benefits of its tests and products.15
Although it has not stated its intent to conduct research, one of the
most recent entries onto the PGT market, Pathway Genomics, has a
significant social networking component. Pathway “provides physicians and their patients with genetic testing reports on diet and exercise, drug response, carrier status, and complex health conditions.”16
Genetic counselors are available for consultation. Pathway also maintains a blog, which addresses genetic news, innovations, and discoveries, in addition to company-focused announcements.17
On its website, the company TruGenetics previously claimed that
the company would scan 500,000 SNPs for approximately 200 traits
and illnesses and would provide access to genetic counselors.18 To
12

deCODEme
Privacy
Policy,
DECODEME,
http://www.decodeme.com/privacy-policy (last updated June 7, 2011).
13
deCODEme Genetic Scan Service Agreement and Informed Consent,
DECODEME, http://www.decodeme.com/service-agreement (last updated June 7,
2011).
14
Andrew Pollack, Google Co-Founder Backs Vast Parkinson’s Study, N.Y.
TIMES, Mar. 12, 2009, at B1, B9.
15
DECODEYOU, http://decodeyou.com/ (last visited Apr. 12, 2011).
16
PATHWAY GENOMICS, http://www.pathway.com/ (last visited Apr. 12,
2011). Pathway, which initially sold its test kits as direct-to-consumer products over
the internet (and at one point intended to sell its kits at Walgreens and CVS stores),
now markets its services only to physicians. Turna Ray, FDA on Pathway’s Class I
Spit Kit Determination: ‘Registration is Not Classification’, PHARMACOGENOMICS
REP. (Oct. 5, 2011), http://www.genomeweb.com/mdx/fda-pathways-class-i-spit-kitdetermination-registration-not-classification.
17
See DNAction Blog, PATHWAY GENOMICS, http://blog.pathway.com/ (last
visited Apr. 12, 2011).
18
TruGenetics
Services,
TRUGENETICS,
http://www.trugenetics.com/services/index.htm (last visited Apr. 12, 2011); TruGenetics Process, TRUGENETICS, http://www.trugenetics.com/process/ (last visited Apr.
12, 2011).
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receive the service, participants would be required to take a personalized risk assessment survey and to store their genetic risk results, survey results, and other information with TruGenetics. The company
also intended to add a social networking element, called TruCommunities. On its website, TruGenetics disclosed that “[o]ne of the main
goals of TruGenetics™ is to develop a unique research database for
conducting genetic studies.”19 In early 2009, TruGenetics declared
that its genome scanning services would be free to its first 10,000
customers.20 However, on August 21, 2009, it announced that its
funding sources had fallen through, and that, for the time being, it
would not be offering genome scanning services.21 Although the
company maintains its website, complete with privacy policy and
terms and conditions, it is not accepting new registrations at this
time.22
23andMe is probably the most popular of the PGT companies on
the market today,23 as much for its approach to genetic testing as its
relationship to Google (Anne Wojcicki, the co-founder of 23andMe, is
19
The company stated that it may conduct research, or “may partner with
another organization, including non-profit and commercial entities, to conduct research.” Terms & Conditions for Genome Scanning Provided by TruGenetics,
TRUGENETICS, http://www.trugenetics.com/about/terms.htm (last visited Apr. 12,
2011) [hereinafter TruGenetics Terms & Conditions]. The Terms and Conditions
continue: “[y]our decision to use TruGenetics’™ services indicates that you are willing to contribute your questionnaire responses and genetic information to the TruGenetics™ research database. This research database will be free of any information that
can be used to trace this data to you . . . . TruGenetics™ may charge a fee for conducting research using this database.” Id.
20
Money for Nothin’ and Your SNPs for Free?, GENOMEBOY.COM (June 19,
2009), http://genomeboy.com/2009/06/19/money-for-nothin-and-your-snps-for-free/
(linking potential customers to the then-current TruGenetics website: TRUGENETICS
(June
21,
2009),
http://web.archive.org/web/20090621083424/http://www.trugenetics.com/? (accessed
by searching for the URL on Internet Archive database); the TruGenetics website has
subsequently been changed to reflect the company’s revised policy).
21
Dan Vorhaus, 10,000 Free Genome Scans too Good to be Tru? TruGenetics Announces Fundraising Difficulties, GENOMICS L. REP. (Aug. 21, 2009),
http://www.genomicslawreport.com/index.php/2009/08/21/free-genome-scans-toogood-to-be-tru-trugenetics-announces-fundraising-difficulties/.
22
Not
Accepting
New
Registrations,
T RU G ENETICS ,
http://www.trugenetics.com/ (last visited Apr. 12, 2011).
23
23ANDME, https://www.23andme.com/ (last visited Apr. 12, 2011); Dan
Vorhaus, A Thanksgiving Tradition: 23andMe Repackages Product, Raises Prices,
L.
REP.
(Nov.
23,
2010),
GENOMICS
http://www.genomicslawreport.com/index.php/2010/11/23/a-thanksgiving-tradition23andme-repackages-product-raises-prices/ (discussing repackaging and repricing by
“23andMe, the most popular provider of direct-to-consumer (DTC) genetic testing
products.”).
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married to Sergey Brin, co-founder of Google).24 23andMe’s innovation stems from its coupling of social networking elements with its
testing service.25
23andMe posts genetic test results for approximately 100 traits
and diseases, along with genealogy and ancestry information (the
“recreational genetics” aspects of the product), on a password protected website.26 23andMe’s blog, “The Spittoon,” provides educational posts about genetics, along with a series entitled “SNPwatch,”
which highlights new research and ties it back to the consumer’s raw
data.27 23andMe customers are encouraged to become active members of the 23andMe community. One blogger, describing his experience with 23andMe, explained,
I get to join groups of fellow subscribers with whom I share
some DNA commonalities, be they connected with health or
haplotype. For some, these will be support groups of those
said to share a significant risk of something awful. For others
it will be a new way to forge genealogical links. New groups
are formed, almost a parody of the idea of biosocial identity
that I envisaged . . . .28

24

Katie Hafner, Silicon Valley Wide-Eyed over a Bride, N.Y. TIMES, May
29, 2007, at C1. Google, which created a business arm solely focused on venturerelated activities in 2009, “invested in 23andMe and Navigenics, two companies
offering consumer genetic testing.” Andrew Pollack, Google’s Venture Arm Invests
(Oct.
1,
2009,
8:37
AM),
in
Biotech
Start-Up,
N.Y.
TIMES
http://bits.blogs.nytimes.com/2009/10/01/googles-venture-arm-invests-in-biotechstart-up/. Allegedly, Brin loaned 23andMe $2.6 million in start-up fees that the company paid back when Google itself became a Series A investor. David Ewing
Duncan, The Glamorous Life of Web 2.0 Genetics, CNNMONEY.COM (Sept. 25,
2009),
http://money.cnn.com/2009/09/25/technology/23andme_alzheimers_avey.fortune/ind
ex.htm. Other investors include Genentech and New Enterprise Associates. Luke
Timmerman, 23andMe Brings Down the Price of Consumer Genetic Tests, Builds Up
(May
24,
2011),
Relations
with
Big
Pharma,
XCONOMY
http://www.xconomy.com/san-francisco/2011/05/24/23andme-moves-beyond-simpleconsumer-dna-sequencing-sets-sight-on-research/.
25
For a thorough description of the social networking aspects of 23andMe,
see Sandra Soo-Jin Lee & LaVera Crawley, Research 2.0: Social Networking and
Direct-to-Consumer (DTC) Genomics, AM. J. BIOETHICS, June 2009, at 35, 35.
26
23ANDME, https://www.23andme.com/ (last visited Oct. 23, 2011).
27
See THE SPITTOON, http://spittoon.23andme.com/ (last visited Apr. 12,
2011).
28
Ian Hacking, Commercial Genome Reading, NAT’L HUMANITIES CTR.
(Mar. 30, 2009), http://onthehuman.org/2009/03/current-controversies-ian-hacking/.

2012]

PGTandME: SOCIAL NETWORKING-BASED GENETIC TESTING

41

23andMe engaged Informed Medical Decisions, Inc. (InformedDNA), a nationwide network of board-certified genetics experts, to offer independent genetic counseling services to its customers.29 Linda Avey, co-founder of the company with Wojcicki, has
spoken out against a “paternalistic” approach to genetic testing, but
has acknowledged that genetic counseling might be required in certain
situations.30
23andMe has devoted its resources to conducting research utilizing genetic and phenotypic information gathered through its services.
According to reports, nearly 90 percent of its 125,000 genotyped customers have opted to participate in research approved by the company’s IRB.31 23andMe’s research arm, 23andWe, was the company’s first attempt to obtain detailed trait information via online surveys of customers.32 The service evolved into more targeted recruitment of specific “research communities” for larger association studies
for Parkinson’s disease,33 sarcoma,34 and pregnancy.35 The first initiative was launched March 7, 2009, and is an effort to recruit 10,000
participants for Parkinson’s disease research. It is funded by Brin,
who allegedly found out through his wife’s company’s test that he
was predisposed to the disease.36 Participants receive all 23andMe’s
services for free and are given access to Parkinson’s disease community forums. As of January 26, 2010, more than 3,500 people with
Parkinson’s disease had submitted saliva samples for genetic analysis
29
Press Release, 23andMe, 23andMe Enlists Informed Medical Decisions to
Make Independent Genetic Counseling Services Available to Customers (June 3,
2010), available at https://www.23andme.com/about/press/20100603/.
30
In September 2009, Avey left 23andMe to start an Alzheimer’s disease
foundation. DNA Test Firm Founder to Start Research Foundation, N.Y. TIMES
(Sept. 4, 2009), available at http://www.nytimes.com/2009/09/05/technology/startups/05bizbriefs-DNATESTFIRMF_BRF.html?_r=1.
31
Bruce V. Bigelow, 23andMe Identifies Possible Protective Gene Against
Parkinson’s Disease, XCONOMY (Oct. 25, 2011), http://www.xconomy.com/sandiego/2011/10/25/23andme-identifies-possible-protective-gene-against-parkinsonsdisease/.
32
Research, 23ANDME, https://www.23andme.com/research/ (last visited
Apr. 12, 2011).
33
23andMe Parkinson’s Community: Strength in Numbers, 23ANDME,
https://www.23andme.com/pd/ (last visited Apr. 12, 2011); On Our Way to 10,000:
23andMe Welcomes First Members of Parkinson’s Disease Community, THE
SPITTOON (Apr. 13, 2009), http://spittoon.23andme.com/2009/04/13/on-our-way-to10000-23andme-welcomes-first -members-of-parkinsons-disease-community/.
34
23andMe Sarcoma Community: A Patient-Driven Revolution in Sarcoma
Research, 23ANDME, https://www.23andme.com/sarcoma/ (last visited Aug. 9, 2011).
35
Pregnancy Community: See Your Pregnancy in a Whole New Light,
23ANDME, https://www.23andme.com/pregnancy/ (last visited Apr. 12, 2011).
36
See Pollack, supra note 14, at B9.
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and answered over 30,000 online surveys.37 In addition, more than
8,000 people without Parkinson’s disease have taken 23andMe’s surveys as control subjects.38 Likewise, individuals who have been diagnosed with sarcoma are encouraged to “take an active role in research
that may benefit you and others living with a similar diagnosis” and to
“[t]ake action against this disease,” by providing a saliva sample for
genetic analysis, completing online surveys about their sarcoma experience and response to treatment, and participating in the “community.”39
In the summer of 2009, 23andMe unveiled Research Revolution,
where anyone—those with the disease to be studied or healthy volunteers who would serve as controls—could participate.40 The principles of the Research Revolution were as follows: participants who
purchased the spit test would then “vote” on a predetermined list of
common diseases on which they would like the company to focus
research.41 For the first wave of votes, from July 7 through September
30, 2009, the diseases and traits on which participants could vote in37
Nick Eriksson & Lizzie Dorfman, 23andMe Parkinson’s Research InitiaSPITTOON
(Jan.
26,
2010),
tive
Progress
Update,
THE
http://spittoon.23andme.com/2010/01/26/23andme-parkinsons-research-initiativeprogress-update/. By March 2011, the study had enrolled more than 5,000 participants with Parkinson’s disease and gathered more than 40,000 data points about their
experiences with the disease. An Update on Our Parkinson’s Research Community,
THE SPITTOON (Mar. 21, 2011), http://spittoon.23andme.com/2011/03/21/an-updateon-our-parkinsons-research-community/.
38
Id.
39
23andMe Sarcoma Community: A Patient-Driven Revolution in Sarcoma
Research, supra note 34.
40
Linda Avey, Introducing a Do-It-Yourself Revolution in Disease Research,
THE SPITTOON (July 7, 2009), http://spittoon.23andme.com/2009/07/07/introducing-ado-it-yourself-revolution-in-disease-research/ (linking readers to a now defunct website, The 23andMe Research Revolution, 23ANDME (Jan. 8, 2010),
http://web.archive.org/web/20100108012414/https://www.23andme.com/researchrevo
lution/ (accessed by searching for the URL on Internet Archive database). For the
first phase of Research Revolution, participants could purchase a limited version of its
testing service at a reduced rate of $99, but 23andMe discontinued offering the service at this rate because, as Andro Hsu, then the Manager of Regulatory & Governmental Affairs at 23andMe, stated, “we found that consumer interest is focused on our
complete product and those users can still pledge to support the program.” Mark
Henderson, Personal Genomics: 23andMe’s Research Revolution is Over…For Now,
(Jan.
7,
2010),
TIMESONLINE
http://web.archive.org/web/20100417152440/http://timesonline.typepad.com/science/
2010/01/personal-genomics-23andmes-research-revolution-is-over-for-now.html
(accessed by searching for the URL on Internet Archive database).
41
Jason Kincaid, 23andMe Launches $99 Kit to Spur its ‘Research Revolution,’ TECHCRUNCH (July 8, 2009), http://techcrunch.com/2009/07/08/23andmelaunches-99-kit-to-spur-its-research-revolution/.
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cluded epilepsy, migraines, psoriasis, rheumatoid arthritis, and severe
food allergies.42 Participants then submitted online surveys and questionnaires related to their “physical traits, health history and behaviors.”43 Any diseases that garnered 1,000 or more votes would become the subject of an association study performed by the company’s
scientists and outside researchers, using the genetic data from the assembled patients and controls. The company called this collaborative,
democratizing research: “research of, by and for the people, directed
and advanced by you.”44 Although Research Revolution itself was
discontinued due to unprofitability, 23andMe’s customers were informed that they could still participate in research by purchasing the
company’s full services.45
In June 2010, a principal investigator at 23andMe, Nicholas
Eriksson, and his colleagues published the first genome-wide association studies (GWAS) on multiple traits ascertained by self-reported
information provided through the internet. The article stated that the
company’s research framework “takes advantage of the interactivity
of the Web both to gather data and to present genetic information to
research participants, while taking care to correct for the population
structure inherent to this study design.”46 Wojcicki, a coauthor, explained, “[i]n this paper, we confirm that self-reported data from our
customers has the potential to yield data of comparable quality as data

42

Id.
Id.
44
Research Revolution—23AndMe, PHARMA STRATEGY BLOG (Aug. 20,
2009),
http://pharmastrategyblog.com/2009/08/research-revolution-23andme.html/
(citing the now defunct “Research Revolution” page of the 23andMe website, The
(Jan.
8,
2010),
23andMe
Research
Revolution,
23ANDME
http://web.archive.org/web/20100108012414/https://www.23andme.com/researchrevo
lution/ (accessed by searching for the URL on Internet Archive database)).
45
Andro Hsu maintained that research will continue to be a fundamental
aspect of 23andMe’s business model: “Research has always been a fundamental part
of our platform. 23andMe is focused on providing a great experience for consumers
while also allowing them to contribute meaningfully to scientific research. We designed our web service to allow customers to participate in research surveys and to be
engaging enough that they will want to return to our site and continue taking new
surveys. We’re seeing more and more active involvement of individuals in the management of their health. 23andMe is part of this shift in focus as far as genetics is
concerned; but we take individuals a step farther by allowing them to be involved in
research.” Henderson, supra note 40.
46
Nicholas Eriksson et al., Web-Based, Participant-Driven Studies Yield
Novel Genetic Associations for Common Traits, 6 PLOS GENETICS 1, 1 (June 2010),
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000993&representation=PDF.
43
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gathered using traditional research methods.”47 The article’s publication was delayed for almost six months, while the editors of the journal considered issues related to ethical review, consent, and data access.48
The public sector has responded to the private sector’s move into
genetic research by offering alternative research initiatives.49 The
47
Press Release, 23andMe, 23andMe Makes New Discoveries in Genetics
Using Novel, Web-based, Participant-driven Methods (June 24, 2010), available at
https://www.23andme.com/about/press/20100624/.
48
Greg Gibson & Gregory P. Copenhaver, Consent and Internet-Enabled
GENETICS
1,
1
(June
2010),
Human
Genomics,
6
PLOS
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000965&representation=PDF.
On June 23, 2011,
23andMe published its second research paper, discovering two novel associations
with Parkinson’s disease using the largest single Parkinson’s cohort to date, in addition to replicating 20 previously identified genetic associations with the disease. See
Chuong B. Do et al., Web-Based Genome-Wide Association Study Identifies Two
Novel Loci and a Substantial Genetic Component for Parkinson’s Disease, 7 PLOS
1,
1
(June
2011),
GENETICS
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1002141&representation=PDF.
49
Some public databases and software for genomic information are already
being developed or are available to non-profit organizations, academic medical centers, and other entities devoted to public research. For example, the International
HapMap Project was established in 2002 as a partnership of scientists and funding
agencies from Canada, China, Japan, Nigeria, the United Kingdom and the United
States to develop a public resource that will help researchers find genes associated
with human disease and drug responses. About the International HapMap Project,
INT’L HAPMAP PROJECT, http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last
visited Apr. 12, 2011). The information produced by the Project will be made freely
available. Id. In phase I, “over 1.1 million SNPs were genotyped in 270 individuals
from 4 worldwide populations.” Gudmundur A. Thorisson et al., A User’s Guide to
the International HapMap Project Web Site, INT’L HAPMAP PROJECT 1 (2005),
http://snp.cshl.org/downloads/presentations/users_guide_to_hapmap.pdf. Likewise,
the 1000 Genomes Project was established in January 2008, as an international effort
to sequence the genomes of approximately 1,200 people from around the world in
order to create the most detailed and medically useful picture to date of human gePROJECT,
netic
variation.
Project
Overview,
1000
GENOMES
http://www.1000genomes.org/about (last visited Oct. 23, 2011). Until recently, the
collected data were available to the worldwide scientific community through freely
accessible public databases. See First Data Release: SNP Data Downloads and Genome Browser Representing Four High Coverage Individuals, 1000 GENOMES
PROJECT (Dec. 23, 2008), http://www.1000genomes.org/announcements/first-datarelease-snp-data-downloads-and-genome-browser-representing-four-high-covera
(“The first set of SNP calls representing the preliminary analysis of four genome
sequences are now available to download through the EBI FTP site and the NCBI
FTP site.”).
See also About Us, THE RARE GENOMICS INSTITUTE,
http://www.raregenomics.org/about.php (last visited Oct. 26, 2011). In December
2011, the National Human Genome Research Institute announced that would give
approximately $300 million to three institutes to continue work on the 1000 Genomes
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Personal Genome Project (PGP) is a public interest, nonprofit response to companies like 23andMe and deCODE Genetics, with the
intention of placing research results in the public domain.50 The PGP
aims to recruit 100,000 participants to share their genome sequences,
related health and physical information, and regularly report their experiences. Participants will also receive online access to their genome
sequences for their own use. To enroll in the project, participants
must take an entrance exam, which covers genetics, regulation, and
the risks and benefits of genetic technologies.51 The second phase of
the project has enrolled over 1,000 individuals whose profiles (both
genetic and phenotypic) are made public on the PGP website.52 Each
subsequent phase will encompass larger and larger numbers of people.
The PGP does not provide genetic counseling.
Despite concerns regarding the inadequacy of DTC genomic tests
to explain the complexity of genetic information in combination with
environmental and lifestyle information,53 the questionable clinical
validity or utility of the tests,54 and the lack of genetic counseling asProject. Susan Young, Funds Dedicated to Personalized Genetics: NIH Aims to Push
Genome-Sequencing into Mainstream Medicine, NATURE NEWS (Dec. 6, 2011),
http://www.nature.com/news/funds-dedicated-to-personalized-genetics-1.9565.
50
See PERSONAL GENOME PROJECT, http://www.personalgenomes.org/ (last
visited Apr. 12, 2011); see also Newsletter #1, PERSONAL GENOME PROJECT (Apr.
2009), http://www.personalgenomes.org/newsletter/01.html.
51
See Kathleen Page et al., PERSONAL GENOME PROJECT STUDY GUIDE,
http://www.pgpstudy.org/index.htm (last visited Apr. 12, 2011).
52
PGP-1K,
PERSONAL
GENOME
PROJECT,
http://www.personalgenomes.org/pgp1k.html (last updated Mar. 30, 2011).
53
A blogger paid by 23andMe through its pregnancy initiative noted, “[t]he
geneticist said that over at 23andMe, they were worried that people would just see the
number and stop reading. That there’d be all these worried people out there, who
might need to be a bit careful—but didn’t need to go and start pricking their fingers
and swearing off chocolate bars, either.” What? Me Worry? My 23andMe Results,
(Apr.
16,
2009),
23ANDME
http://agelessbodytimelessmom.wordpress.com/2009/04/16/what-me-worry-my23andme-results/. Most identified risk-marker alleles confer incredibly small risks,
between 1.1—1.5. Peter Kraft & David J. Hunter, Genetic Risk Prediction—Are We
There Yet?, 360 NEW ENGL. J. MED. 1701, 1701 (2009).
54
See Gail Javitt et al., Developing the Blueprint for a Genetic Testing Registry, 13 PUB. HEALTH GENOMICS 95, 96 (2009) (“While the number of genetic tests
continues to grow, publicly accessible information about the analytic and clinical
validity of such tests is lagging,” and supports the HHS Secretary’s Advisory Committee on Genetics, Health and Society’s 2008 recommendation to develop a clinical
registry, for “a more transparent, quality-centered system of oversight that will better
inform and protect the public.”). Based on a white paper issued by 23andMe, Navigenics, and DeCODE Genetics that described how the companies calculate genetic
risk, using voluntary industry standards they had developed with the help of the Personalized Medicine Coalition, Muin Khoury, Director of CDC’s Office of Public
Health Genomics, stated that companies still diverge on clinical validation issues
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sociated with DTC genetic testing,55 such tests have been proliferating.56 Among the most visible are those provided by companies such
as Navigenics,57 Inherent Health,58 23andMe, deCODE Genetics,
Knome, and Pathway Genomics, all of whom promise consumers
knowledge and control over their genetic destinies—and, in many
cases, the opportunity to participate in, or even drive, genetic research.59
Although companies like deCODE Genetics and TruGenetics
have floundered in the recent economic environment, the opportunity
critical to protecting consumer health. Turna Ray, More Work Needed to Standardize
Consumer Genomics Offerings, Top US Health Official Says, GENOMEWEB.COM
(Apr. 15, 2009), http://www.genomeweb.com/dxpgx/more-work-needed-standardizeconsumer-genomics-offerings-top-us-health-official-?page=show; see also Eline
Bunnik et al., How Attitudes Research Contributes to Overoptimistic Expectations of
Personal Genome Testing¸ AM. J. BIOETHICS, June 2009, at 23, 24. Recent studies
have emphasized the “recreational” nature of genomic testing, focusing on the limited
predictive capacity of current tests to determine risk. See Kraft & Hunter, supra note
53, at 1701-03; see also David B. Goldstein, Common Genetic Variation and Human
Traits, 360 NEW ENGL. J. MED. 1696, 1698 (2009).
55
See NAT’L INST. HEALTH, HANDBOOK: HELP ME UNDERSTAND GENETICS,
111 (Nov. 7, 2011), available at http://ghr.nlm.nih.gov/handbook.pdf.
56
For excellent overviews and descriptions regarding genetics, genomics,
and genetic testing, see Gail H. Javitt et al., Direct-to-Consumer Genetic Tests, Government Oversight, and the First Amendment: What the Government Can (and Can’t)
Do to Protect the Public’s Health, 57 OKLA. L. REV. 251, 255-56 (2004); Lori Andrews & Erin Shaughnessy Zuiker, Ethical, Legal, and Social Issues in Genetic Testing for Complex Genetic Disease, 37 VAL. U. L. REV. 793, 798 (2003).
57
Founded in 2006, Navigenics’ PGT service does not offer genealogy services or a social networking component, but does maintain a blog that gives lifestyle
tips, provides updates on the company, and discusses genes for which Navigenics
tests. See NAVIGENICS, http://www.navigenics.com/ (last visited Apr. 12, 2011); The
Navigator-Navigenics Blog, NAVIGENICS, http://blog.navigenics.com/ (last visited
Apr. 12, 2011).
58
Interleukin Genetics markets a number of “Inherent Health™” genetics
GENETICS,
tests.
About
Interleukin
Genetics,
INTERLEUKIN
http://www.ilgenetics.com/content/about-interleukin/index.jsp (last visited Apr. 12,
2011). Inherent Health genetics tests require a consent form for all consumers of their
tests, specifically “to document that the person providing their DNA sample to Inherent Health for analysis has done so voluntarily.” Frequently Asked Questions,
INHERENT HEALTH, http://www.inherenthealth.com/faq.aspx (last visited Apr. 12,
2011). Inherent Health informs its clients that “[y]ou own your genetic data. As a
result, only you are able to access and download your genetic data and test results.
Furthermore, you cannot be forced to reveal the results of your genetic test to anyone
else.” Id.
59
Almost all of these companies state in some form that their products are
not designed to diagnose, prevent, or treat any condition or disease but are intended
for educational, informational, and research purposes only. See, e.g., Consent Document, 23ANDME, https://www.23andme.com/about/consent/ (last visited Apr. 12,
2011).
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for PGT companies to contribute to and transform the model for research is still very real. The success or failure of one company cannot
predict the success or failure of the industry as a whole. David Altshuler, a medical geneticist at the Massachusetts General Hospital,
cautioned, “[i]t would be a mistake to draw any connection between
the medical promise of the human genome and the success of a specific company and business model.”60
II.

A NEW RESEARCH PARADIGM?: TOWARD A PERSONAL
GENOMIC TESTING/SOCIAL NETWORKING HYBRID

As the number of clinical trials in the United States multiply and
studies require greater numbers of participants, recruitment of research participants becomes increasingly difficult.61 By March 2009,
there were approximately 50,000 clinical trials underway, of which 80
percent were delayed at least a month due to low enrollment.62 Consequently, researchers and sponsors of research are seeking access to
potential research populations in new and different ways.
At the same time, more and more individuals are seeking health
information from the internet. A 2006 Pew Research Center study
found that 80 percent of internet users in the United States obtain
health information online,63 a statistic that is likely to increase as online communities and social networking sites continue to multiply.
And a more recent study found that one in four internet users living
with high blood pressure, diabetes, heart conditions, lung conditions,
and cancer have gone online to find others with similar health concerns.64 The PatientsLikeMe Genetics Search Engine65 allows pa60
Nicholas Wade, A Genetics Company Fails, Its Research Too Complex,
N.Y. TIMES, Nov. 18, 2009, at B2.
61
Susan Gilbert, Trials and Tribulations, 38 HASTINGS CTR. REP. 14, 14
(2008); Kenneth A. Getz et al., Assessing the Impact of Protocol Design Changes on
Clinical Trial Performance, 15 AM. J. THERAPEUTICS 450 (2008).
62
Sarah Kliff, Pharma’s Facebook: Research 2.0: How Drug Companies
are Using Social Networks to Recruit Patients for Clinical Research, DAILY BEAST
(Mar. 9, 2009), http://www.thedailybeast.com/newsweek/2009/03/10/pharma-sfacebook.html.
63
Susannah Fox, Online Health Search 2006, PEW INTERNET & AMERICAN
LIFE
PROJECT
4
(Oct.
29,
2006),
http://www.pewinternet.org/~/media//Files/Reports/2006/PIP_Online_Health_2006.p
df.pdf.
64
Susannah Fox, Peer-to-Peer Healthcare, PEW INTERNET & AMERICAN LIFE
PROJECT
2
(Feb.
28,
2011),
http://pewinternet.org/~/media//Files/Reports/2011/Pew_P2PHealthcare_2011.pdf.
Very few internet users check the source and date of the information they find. Fox,
supra note 63, at iii.
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tients to “share genetic information and find others like them by the
gene (and even the specific mutation in that gene) causing their condition.”66 The co-founder of PatientsLikeMe described the system as
helping to “realiz[e] the goals of personalized medicine today,”67 and
the company emphasizes the democratization of data and research
enabled by its “openness philosophy.”68
Likewise, pharmaceutical companies have begun to take advantage of the research recruitment opportunities afforded by social networking. Online networking sites like Inspire.com and PatientsLikeMe allow users to receive targeted information from pharmaceutical companies who use the site as a recruiting tool for drug studies.69
In 2008, a partnership between Novartis and PatientsLikeMe led to
the first effort to recruit research participants for a study (in this case,
for a multiple sclerosis drug) through a social network.70 In a similar
effort, Pfizer announced its intention to create an online community to
increase clinical trial participation, in collaboration with Private Access, a health information technology company.71
65

PATIENTSLIKEME, www.patientslikeme.com (last visited Sept. 17, 2009).
PatientsLikeMe allow registrants to record, monitor, and share symptoms, severity,
progression, and treatment (including drug regimens and dosages) on the site. See id.
In April 2011, it opened its online community to people with all types of illnesses,
rather than restricting it to patients with particular chronic diseases. PatientsLikeMe
Calls All Patients with Any Condition to Join, PATIENTSLIKEME (Apr. 11, 2011),
http://blog.patientslikeme.com/2011/04/11/patientslikeme-calls-all-patients-with-anycondition-to-join/.
66
Press Release, PatientsLikeMe, PatientsLikeMe Launches Genetics Search
Engine
for
ALS
Patients
(Apr.
22,
2009),
available
at
http://www.patientslikeme.com/press/20090422/15-patientslikeme-launches-geneticssearch-engine-for-als-patients.
67
David S. Williams III, Our Philosophy, PATIENTSLIKEME,
http://www.patientslikeme.com/about/openness/ (last visited Sept. 26, 2011) (“PatientsLikeMe enables you to [a]ffect a sea change in the healthcare system. We believe that the Internet can democratize patient data and accelerate research like never
before. Furthermore, we believe data belongs to you the patient to share with other
patients, caregivers, physicians, researchers, pharmaceutical and medical device companies, and anyone else that can help make patients’ lives better. Will you add to our
collective knowledge… and help change the course of healthcare?”).
68
David S. Williams III, The Value of Openness, PATIENTSLIKEME (Dec. 13,
2007, 3:50 PM), http://blog.patientslikeme.com/2007/12/13/the-value-of-openness/.
69
Kliff, supra note 62.
70
Id. “In May 2008, the site sent out a message to the 8,000 members of
their multiple-sclerosis community, alerting them to the Novartis trial. From that email, nearly 1,500 members visited the Novartis website. After recruiting through
PatientsLikeMe.com, Novartis saw a boost in registrations for the study, although
they did not track which or how many individuals enrolled because of the campaign—due to patient privacy concerns.” Id.
71
The site will “focus on patient privacy rights to connect patients, physicians and researchers with tailored information, tools and technology that will lead to
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Even before PGT companies entered the fray, commentators had
already begun considering the pros and cons of online targeted recruitment.72 The proliferation of social networking sites offers researchers and research sponsors the opportunity to access databases of
personal, genetic, and health-related information. Crowd-sourcing
enables pharmaceutical companies to “get easy online access to highly
engaged populations with specific medical conditions.”73 Online recruitment allows potential participants who might never have heard
about such studies otherwise, due to geography or other reasons, to
decide whether enrollment is right for them. Social networking aids
recruitment, as participants enlist others from among their connections
within their network.74
Although many of the features of research resulting from PGT
and social networking are new, a number of the underlying issues
have been discussed at length in the context of biobanks.75 Biobanks
serve as repositories of biological specimens, which can be analyzed
to identify gene variations associated with human diseases. Typically,
samples are collected during routine clinical and surgical procedures76
more informed decisions about patient care, including clinical trial participation industry-wide.” Pfizer and Private Access Announce Plans to Develop Online Community to Accelerate Clinical Research, BUSINESS WIRE (Aug. 19, 2009),
http://www.businesswire.com/news/home/20090819005806/en/Pfizer-PrivateAccess-Announce-Plans-Develop-Online.
72
In an in-depth piece in August 2009, the New York Times examined the
practice of collecting patient data and genetic information online to use in recruiting
patients for clinical trials, conducting research internally or to sell to drug and biotechnology companies. Sarah Arnquist, A Research Trove: Patients’ Online Data,
N.Y. TIMES, Aug. 25, 2009, at D1; see also Editorial, Calling All Patients, 26
NATURE BIOTECHNOLOGY 953 (2008).
73
Kliff, supra note 62.
74
Dan O’Connor, Apomediation and the Significance of Online Social Networking, AM. J. BIOETHICS, June 2009, at 25, 26.
75
For comprehensive considerations of the legal and ethical issues as they
relate to biobanks, see, e.g., Karen J. Maschke, Biobanks: DNA and Research, in
FROM BIRTH TO DEATH AND BENCH TO CLINIC: THE HASTINGS CENTER BIOETHICS
BRIEFING BOOK FOR JOURNALISTS, POLICYMAKERS, AND CAMPAIGNS 11, 12-13 (Mary
Crowley
ed.,
2008),
available
at
http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/biobank
s%20dna%20and%20research.pdf; The National Bioethics Advisory Commission,
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance
(Aug. 1999), available at http://bioethics.georgetown.edu/nbac/hbm.pdf; THE ETHICS
OF RESEARCH BIOBANKING (Jan Heldge Solbakk, Soren Holm & Bjorn Hofmann, eds.,
2009); ROBERT F. WEIR & ROBERT S. OLICK, THE STORED TISSUE ISSUE: BIOMEDICAL
RESEARCH, ETHICS, AND LAW IN THE ERA GENOMIC MEDICINE (2004).
76
Maschke, supra note 75, at 11 (citing ELISA EISEMAN & SUSANNE B.
HAGA, HANDBOOK OF HUMAN TISSUE SOURCES: A NATIONAL RESOURCE OF HUMAN
TISSUE SAMPLES (1999)).
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or by research initiatives that collect, store, and distribute samples and
data to researchers.77 Recently, biotech companies have begun to
build biobanks for the sole purpose of selling or licensing samples and
data to researchers.78 The circumstances by which samples are collected and obtained may shed new light on the gaps in regulation and
law as they relate to these issues.
The move toward online collaboration and the “democratization”
of data can be seen in the greater context of the transformation of the
“networked information economy.”79 The “basic change in the material conditions of information” due to the increase in electronic information sharing has been credited with shifting the role of the participant and rendering information communication collaborative instead
of a single-direction endeavor.80
Ultimately, many of the PGT companies’ business models do not
focus on profits from the sale of genetic tests, but from gathering the
genetic and personal data that can be licensed and sold to institutions,
academic researchers, or drug companies.81 Thus, these companies’
mission statements, websites, and advertisements are potentially misleading, convincing PGT consumers that they are either (1) purchasing a recreational service to track ancestry or predisposition to genetic
conditions, or (2) driving in-house research efforts to find cures and
benefit society.

77
Id. For example, the author cites the Children’s Hospital of Philadelphia
project to collect blood samples from more than 100,000 children as part of a genetic
research initiative to study the most prevalent childhood diseases.
78
See, e.g., Anita Huslin, Firm Carves New Model in Biotech Research,
WASH. POST, Dec. 17, 2007, at D1.
79
For example, intellectual property scholar Yochai Benkler is an advocate
of collaborative research and peer production on the internet and discusses the networked information economy. See, e.g., Yochai Benkler, Freedom in the Commons:
Towards a Political Economy of Information, 52 DUKE LAW J. 1245, 1246, 1251,
1255-56 (2003).
80
Id. at 1250 (discussing the decentralizing of the distribution of information
function). Benkler describes the “commons-based peer production” as “a process by
which many individuals, whose actions are coordinated neither by managers nor by
price signals in the market, contribute to a joint effort that effectively produces a unit
of information or culture.” Id. at 1256.
81
David P. Hamilton, 23andMe’s Price Cut: The End of Commercial Personal
(Sept.
9,
2008),
Genomics?,
BNET
HEALTHCARE
http://industry.bnet.com/healthcare/1000151/23andmes-price-cut-the-end-ofcommerical-personal-genomics/. However, many companies’ business models focus
on the money to be made from genetic genealogy and ancestry testing. Daniel
MacArthur, Cheap Personal Genomics: The Death-Knell for the Industry?,
WIRED.COM
(Sept.
10,
2008,
11:58
AM),
http://scienceblogs.com/geneticfuture/2008/09/cheap_personal_genomics_the_de.php
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SHIFTS IN RESEARCH STRUCTURE, TIMING, LOCUS, AND
SCOPE

The concerns related to genome-wide research resulting from the
PGT/social networking hybrid require thoughtful consideration, particularly in light of transformations in the way that research is done
and how participants are recruited. The where, when, who, and how
of research is shifting, intensified by the fact that all interactions between research participant and investigator occur online. Some of
these shifts are considered below.
A.

Shift in the Scope of Use of Genomic and Personal
Data

Under the typical model for recruitment for clinical research, participants are enrolled in studies with an established and IRB-approved
protocol, and when that study ends, they are no longer research participants. However, once a PGT company has access to one’s genomic data and the results of surveys revealing physical, behavioral,
and other personal information, it could ostensibly utilize that data in
studies ad infinitum. Thus, potential participants will most likely not
be signing on for a single, targeted test. Instead, participants’ genetic
and phenotypic data might be used for any number of studies, focused
on any number of genetic traits or illnesses, and overseen and conducted by any number of investigators. As with biobanked data, the
use of an individual’s genomic and/or phenotypic information in innumerable studies that were not identified at the time of enrollment
challenges current expectations of how research protocols are defined
and what it means to participate in research.82
B.

Shift in the Role of the Participant: Patient-Driven
Research?

Many commentators have applauded the model of participantdriven research—research that is spurred by and recruited from members of online social networks—as “novel and powerful,” exclaiming
that it will “increasingly come to dominate the genomic research land-

82
Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS), 72 Fed. Reg. 49,290, 49,291 (Aug. 28,
2007).
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scape.”83 Scholars may welcome the idea of patient-driven research
as part of the “commons-based peer production of information [and]
knowledge . . .,” which permits the “emergence of . . . radically new
roles that individuals play in the production process.”84 If 23andMe’s
research agenda is successful in recruiting large numbers of participants, the initiative could set the stage for progress in terms of recruitment and enrollment.85 Wojcicki described the shift to patientdriven research as “patient empowerment,” explaining that “[t]wenty
years ago doctors had tight control over all medical information. We
want that power to shift to individuals.”86
However, it is unclear that customers who contribute genetic and
personal information for research purposes are “driving” research.
Under 23andMe’s Research Revolution model, collaboration consisted of a simple “vote” for the disease on which research would be
focused—a vote purchased with both cash and release of information
including genetic data, physical traits, health history, and behavior.
Thus, beyond contribution of genetic and phenotypic information, it is
questionable that participants would truly be directing research. They
did not have a say in the contours of the research or selection of the
investigators who would conduct the studies. The power to make all
these decisions remained in the hands of the research sponsor (in this
case, 23andMe and its partners). Significantly, the fact that the research participants may never know how their information is being
used in a particular study directly conflicts with the notion that participants are driving research. Thus, it is unclear whether this approach to genetic research is truly democratizing, or is simply an illusion of collective production.

83

Daniel MacArthur, The Future of Participant-Driven Genomic Research,
(Mar.
12,
2009,
1:10
PM),
WIRED.COM
http://www.wired.com/wiredscience/2009/03/The-future-of-participant-drivengenomic-research.
84
Benkler, supra note 79, at 1254-55.
85
Daniel MacArthur, 23andMe Launches New Effort to Recruit Patients for
(July
7,
2009,
8:00
PM),
Disease
Gene
Studies,
WIRED.COM
http://scienceblogs.com/geneticfuture/2009/07/23andme_launches_new_effort_to.php
(“Modern genomics studies require mind-bogglingly large numbers of samples to
achieve the power required to find subtle genetic associations, and recruiting those
numbers of patients is far from easy.”).
86
Getting Personal, THE ECONOMIST, Apr. 18, 2009, at 9.
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Shift in the Role of the Participant: Participant
Self-Organization and Self-Identification

As patients organize into online communities and self-identify for
participation in research, recruitment and enrollment practices in
clinical research may begin to transform.87 For example, although
research arising out of the PGT/social networking hybrid may not be
as collaborative as the companies claim, the notion of having patients
self-organize into an online community for a study may still elevate
the participant to a position of greater authority.88
Moreover, self-selection may cause the breakdown of the screening process which has developed over the years to ensure the safety of
participants as well as the reliability of the resulting data. With no
one to screen participants for eligibility, the possibility of selection
and attrition bias and mis- or over-reporting of symptoms and traits
will likely increase, undermining the integrity of the data generated
from such studies.89 In fact, despite deCODE Genetics’ apparent entry into the field of research in 2009, its CEO had publicly stated that
such research may not be useful, because self-reported phenotypes
are, by and large, unreliable.90 In addition, self-organizing might be
problematic because, where participants are also providing personal
information, “[u]ser-generated data is highly variable and poorly controlled.”91 The head of exploratory clinical development at Novartis,
Trevor Mundel, stated, “[i]t’s something which hasn’t been worked
through, how [social networks] might worsen the accuracy of adverseevent reporting.”92 These concerns about accuracy are compounded
by the fact that, in research arising from the PGT/social networking
87
Eric S. Lander, the Founding Director of the Broad Institute of MIT and
Harvard, has stated that the idea of having patients “self-organize” into an online
community for a study, rather than be recruited, is “a Googley thing to do.” Pollack,
supra note 14, at B9.
88
It has been noted that investigators may not appreciate the “intrusion” of
patients or patient advocates into their research. See Do-it-Yourself Science, 449
NATURE 755, 756 (2007).
89
For example, as patients in the same study might communicate with and
reveal significant information to one another on social networking sites, they could
possibly deduce who is taking the test drug versus placebos. Kliff, supra note 62; see
also Arnquist, supra note 72, at D6.
90
Mark Henderson, Cashing in on Your Genes: Will Personal DNA Testing
Soon be Big Business and Will Our Genetic Data be Safe?, TIMES (London) (Jan. 7,
2010),
available
at
http://www.timesonline.co.uk/tol/news/science/eureka/article6975520.ece?token=null
&offset=0&page=1.
91
Calling All Patients, supra note 72.
92
Kliff, supra note 62.
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hybrid, research participants and investigators never meet, which may
further transform how participants view their own role in the research
and hinder investigators’ ability to gauge the veracity of research subjects and the quality of the data.
D.

Expectations of Care and Intensifying the Therapeutic Misconception

The marketing and promotion for initiatives like 23andMe’s research agenda might mislead participants to think that, even if they
may not benefit financially from their participation, they will benefit
medically and therapeutically.93 The promises of collaboration and
democratization could exacerbate an already very real problem—the
therapeutic misconception—that arises when research participants do
not understand the distinction between treatment and research.94 This
is particularly relevant where companies have two primary and seemingly unrelated purposes: providing genetic and ancestry information
Currently,
to customers and developing research databases.95
23andMe, Pathway Genomics, TruGenetics, and even the PGP offer,
or plan to offer, both genetic screening services and the opportunity to
participate in genome-wide research. Critics of DTC genetic testing
already point out that these companies may be overpromising the
therapeutic advantages of these tests. When the therapeutic misconception is coupled with the promises of research—which is not intended to provide clinical benefits—participants may become further
confused or misled as to the benefits of participation.
This confusion may intensify due to the lack of mandatory genetic
counseling for participants. Only some PGT companies offer any
genetic counseling services.96 For many participants, there is no one
to dispel the therapeutic misconception, particularly in the absence of
93
In the non-research context, most, if not all, PGT companies disclose the
fact that customers should not expect medical benefits for their testing services, and
that test results are no substitute for physician-provided medical care. However, in
the research setting, the lines easily become more blurred.
94
See Paul S. Appelbaum et al., Therapeutic Misconception in Clinical Research: Frequency and Risk Factors, 26 IRB: ETHICS & HUM. RES., Mar.-Apr. 2004,
at 1, 1; Paul S. Appelbaum et al., Correction and Clarification, 26 IRB: ETHICS &
HUM. RES., Sept.-Oct. 2004, at 18, 18.
95
For example, TruGenetics declares that its services will “help you explore
your genes.” TruGenetics Process, supra note 18. On a separate page, TruGenetics
also states that “[o]ne of the main goals of TruGenetics is to develop a unique research database for conducting genetic studies.” TruGenetics Terms & Conditions,
supra note 19.
96
As of this writing, these companies include Navigenics, deCODE Genetics, Pathway Genomics, and 23andMe.
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a physician-intermediary or investigator to explain test results, describe research protocols, and answer questions.
LEGAL, ETHICAL, AND REGULATORY CONSIDERATIONS
FOR RESEARCH

IV.

These shifts in who, when, how, and where give rise to a number
of practical issues, and a thorough consideration of these shifts reveals
gaps in the current regulatory and legal regime for protecting participants in research studies. In particular, the areas of concern include
the informed consent process during recruitment and enrollment, lack
of IRB oversight, and confused expectations related to therapeutic
benefits. The regulatory checks and controls applied to other types of
research may not be comprehensive or targeted enough to address the
problems that arise out of social networking-based genetic research.
The well-known 2003 lawsuit between the Havasupai Tribe in
Arizona and the Arizona Board of Regents and the University of Arizona and Arizona State University highlights some of the ethical issues related to the collection and use of DNA samples, even without
the use of social networking technologies. Members of the tribe alleged that the defendants had used blood samples submitted solely for
diabetes research for genetic research into schizophrenia, inbreeding,
and ancient population migration.97 Among a number of publications
and research projects that relied on the misused data were four doctoral dissertations and a number of academic papers, many of which
were completely unrelated to the research to which the Havasupai had
agreed.98 In April 2010, the University’s Board of Regents settled,
agreeing to pay $700,000 to members of the tribe, return the blood
samples obtained between 1990 and 1994, and provide other forms of
assistance.99
Many of the ethical and legal considerations concerning the collection and use of genetic and phenotypic data—particularly those
related to informed consent—become even more pronounced with
97

Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063, 1066 (Ariz. Ct.
App. 2008). After the Arizona Court of Appeals ruled that the tribe could sue the
Arizona Board of Regents and the Universities, the Arizona Supreme Court agreed to
hear the appeal of one of the researchers. Havasupai Tribe v. Ariz. Bd. of Regents, No. CV-09-007-PR, 2009 Ariz. LEXIS 82 (Apr. 20, 2009).
98
Of particular concern to the Havasupai Tribe was the fact that many of the
papers related to theories about ancient human population migrations from Asia to
North America, which is contrary to their belief that the tribe originated in the Grand
Canyon. Havasupai Tribe, 201 P.3d at 1067.
99
Amy Harmon, Tribe Wins Fight to Limit Research of its DNA, N.Y.
TIMES, Apr. 22, 2010, at A1.
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research conducted under genome-wide initiatives using online services. Some investigators have highlighted the implications of publishing and sharing aggregate genomic data, particularly considering that,
despite aggregation, it may be possible to identify (or re-identify) an
individual’s genomic data within a large pool of data.100 The authors
of one article concluded that, “the policies and practices guiding genomic data sharing should continue to evolve in order to promote
quality science, minimize duplicative research and merit the ongoing
trust of the research subjects who consent to participate in scientific
studies.”101
A.

Current Human Subjects Recruitment and Enrollment Law as it Applies to Social NetworkingBased Genetic Research

Commentators have noted confusion about when the federal rules
and regulations governing research with humans apply to research
with biospecimens and the associated data.102 Concerns about informed consent for participants in research arising from PGT databases are particularly acute, since empirical literature indicates that
most people are willing to grant consent for genetic studies.103 But,
investigators are often not able—or not required—to obtain consent
for use of collected or stored samples.
The Common Rule, the law governing human subject research in
the United States for research conducted or supported by any of eighteen federal departments or agencies, regulates informed consent.104
100

Nils Homer et al., Resolving Individuals Contributing Trace Amounts of
DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays,
GENETICS
1,
2,
7,
9
(Aug.
2008),
PLOS
http://www.plosgenetics.org/article/fetchObjectAttachment.action?uri=info%3Adoi%
2F10.1371%2Fjournal.pgen.1000167&representation=PDF; Kevin B. Jacobs et al., A
New Statistic and Its Power to Infer Membership is a Genome-Wide Association
Study Using Genotype Frequencies, 41 NATURE GENETICS 1253, 1253 (2009); Sriram
Sankararaman et al., Genomic Privacy and Limits of Individual Detection in a Pool,
41 NATURE GENETICS 965, 965 (2009).
101
Jacobs, supra note 100, at 1257.
102
Maschke, supra note 75, at 11, 12-13 (“Some rules conflict with each
other, and there are differences in how the rules define ‘research,’ ‘human subjects,’
and ‘identifiable’ personal information. How these terms are defined determines
whether IRBs must approve biospecimen research, and whether individuals must give
consent for use of their stored biospecimens or their identifiable genetic and other
medical information.”).
103
David Wendler, One Time General Consent for Research on Biological
Samples, 332 BRIT. MED. J. 544, 547 (2006).
104
See 45 C.F.R. § 46 (2010).
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The Common Rule defines research as “a systematic investigation,
including research development, testing and evaluation, designed to
develop or contribute to generalizable knowledge.”105 It requires that
investigators explain to participants the purposes of their research, the
mechanisms to ensure confidentiality, the existence of IRB oversight
of the research protocol and consent process, and the risks of the research.106 In terms of risk, there may be little individual physical risk
in social networking-related genetic research because of the lack of
clinical implications for the participant. However, individual informational risks and group harms are a very real possibility.107 Populationbased genomic research could lead to further stigmatization or discrimination against racial or ethnic groups.
Whether research utilizing biospecimens collected as part of a
PGT service constitutes human subjects research under the Common
Rule is unsettled.108 Although, in some cases, even filling out a basic
paper survey falls under the umbrella of research, survey procedures
are exempt from the Common Rule, unless the information is directly
or indirectly identifiable and any disclosure outside the research could
reasonably place the subjects at risk of liability or be damaging to the
subject’s financial standing, employability, or reputation.109 However,
contribution of biological samples and genetic information goes beyond simple survey procedures, and the revelation of personal behavioral and physical information as well as family history could easily
affect employability and reputation. Guidance issued by the Office of
Human Research Protections (OHRP) suggests that studies using
samples that were not collected for the purpose of research “through
an interaction or intervention with living individuals,” and for which
“the investigator(s) cannot readily ascertain the identity of the individual(s) to whom the coded private information or specimens pertain,” do not constitute human subjects research.110 However, com105

Id. § 46.102(d).
Id. § 46.116.
107
Laura M. Beskow et al., Informed Consent for Population-Based Research
Involving Genetics, 286 JAMA 2315, 2318 (2001); Marc D. Schwartz et al., Consent
to the Use of Stored DNA for Genetics Research: A Survey of Attitudes in the Jewish
Population, 98 AM. J. MED. GENETICS 336, 336 (2001) (“[P]articipants were significantly less willing to participate in research that examined stereotypical or potentially
stigmatizing traits as opposed to research that examined medical or mental illnesses.”).
108
See Christian M. Simon et al., Active Choice but Not Too Active: Public
Perspectives on Biobank Consent Models, 13 GENETICS MEDICINE 821, 821 (2011).
109
45 C.F.R. § 46.101(b)(2).
110
OHRP, Guidance on Research Involving Coded Private Information or
Biological
Specimens
(Oct.
16,
2008),
available
at
http://www.hhs.gov/ohrp/policy/cdebiol.html; see also Human Subjects Research
106
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mentators have noted that it is generally recognized that informed
consent is necessary before an individual contributes biological samples for research.111
Recently proposed revisions by the Department of Health and
Human Services (HHS) and the Office of Science and Technology
Policy would do much to clarify the extent and scope of the Common
Rule for research conducted using biospecimens.112 The Advance
Notice of Proposed Rulemaking (ANPRM) recommends the most
substantive changes to the Common Rule in approximately twenty
years, in response to the transforming and expanding research enterprise. Generally, it proposes a series of modifications in order to increase protections of research participants while reducing burden,
delay, and ambiguity for investigators.113 First, the ANPRM would
expand the scope of the Common Rule’s authority, applying the protections contained therein to all studies, regardless of funding source,
that are conducted at United States institutions that receive some federal funding for human subjects research from a Common Rule department or agency.114 Notably, it would extend the informed consent
requirements for research on biospecimens and require that an individual give consent, in writing, for research use of their biospecimens.115 However, the ANPRM envisions that consent may be onetime and general, rather than study specific, and would cover all future research.116 At donation, individuals may choose not to sign a
Protections: Enhancing Protections for Research Subjects and Reducing Burden,
Delay, and Ambiguity for Investigators, 76 Fed. Reg. 44,512, 44,519 (July 26, 2011)
(acknowledging that “the current rules… allow research without consent when a
biospecimen is used for research under conditions where the researcher does not
possess information that would allow them to identify the person whose biospecimen
is being studied.”).
111
Wendler, supra note 103, at 547.
112
See Human Subjects Research Projections: Enhancing Protections for
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76
Fed. Reg. at 44,512. The ANPRM was issued, in part, in response to allegations that
“uncertainty about the regulations on biospecimens has impeded research.” Ezekiel
Emanuel & Jerry Menikoff, Reforming the Regulations Governing Research with
Human Subjects, 365 NEW ENGL. J. MED. 1145, 1148 (2011).
113
See Human Subjects Research Projections: Enhancing Protections for
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76
Fed. Reg. at 44,512.
114
Id. at 44,528.
115
Id. at 44,515.
116
In a comment addressing the ANPRM, the Secretary’s Advisory Committee on Human Research Protections (SACHRP) advised against general consent for
all future uses of biospecimens as a way to protect participants from harm. See Letter
from Barbara E. Bierer, Chair, Secretary’s Advisory Committee on Human Research
Protections, to the Honorable Kathleen Sebelius, Secretary of Health and Human
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standardized general consent form granting open-ended consent; in
such cases, they may prohibit the use of their biospecimens for future
research. Further, the proposed modifications would eliminate the
distinction between research on biospecimens collected for research
and nonresearch purposes.117 This last point directly implicates research conducted on biospecimens collected through social networking PGT sites, as often these samples are not collected for the purpose
of research, although the companies may then seek to use and share
the data for that reason.
The Health Insurance Portability and Accountability Act (HIPAA)
restricts how certain identifiable health information may be used and
disclosed, including for research.118 Genetic information is protected
to some extent under HIPAA, after being amended by the Genetic
Information Nondiscrimination Act (GINA) to include “genetic inHowever,
formation”
as
“health
information.”119
anonymized biological material is not considered protected health
information under HIPAA.120 Because of the ease of re-identification
Services
43-45
(Oct.
2011),
http://www.dfhcc.harvard.edu/fileadmin/DFHCC_Admin/Clinical_Trials/OPRS/Form
s_Instructions/ANPRM/SACHRP_ANPRM_comment.pdf (“[N]o researcher would
have a reliable way of predicting, for purposes of informed consent adequate under
the Common Rule, the full range of specific future uses of data and biospecimens that
would be widely acceptable to American society in 25, 50, or 100 years; such a general future consent therefore could not be sufficient under the Common Rule to obviate the necessity, prior to a researcher’s undertaking a later specific study, of applying
to an IRB for waiver of informed consent.”).
117
Human Subjects Research Projections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76
Fed. Reg. at 44,527.
118
Health Insurance Portability and Accountability Act of 1996, Pub. L. No.
104-191, 110 Stat. 1936, 2023. The HIPAA rules apply only to health plans, healthcare clearinghouses, and certain health-care providers, and not all investigators are
part of a covered entity. See Human Subjects Research Projections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 Fed. Reg. at 44,514. However, it has been argued that HIPAA is ineffective in protecting personally identifiable information (PII). See Arvind Narayanan
& Vitaly Shmatikov, Myths and Fallacies of “Personally Identifiable Information,”
COMM. ACM, June 2010, at 24, 26 (“PII has no meaning even in the context of the
HIPAA Privacy Rule.”).
119
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233,
§1180, 122 Stat. 881, 904.
120
In July 2010, the HHS proposed two new provisions to HIPAA intended to
streamline the process for obtaining informed consent for clinical trial participation
and authorization for use of protected patient data and biological materials. Modifications to the HIPAA Privacy, Security, and Enforcement Rules Under the HITECH
Act; Proposed Rule, 75 Fed. Reg. 40,868 (proposed July 14, 2010) (to be codified at
45 C.F.R. pt. 164). The first provision allows for compound authorizations which
would allow use of a single informed consent document for both enrollment in a
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(and the “impossibility” of full de-identification) of biospecimens, the
July 2011 ANPRM recommends adopting the HIPAA standards for
purposes of the Common Rule regarding what constitutes individually
identifiable information and de-identified information, and categorizing all research involving the collection of biospecimens as well as
storage and secondary analysis of existing biospecimens as research
involving identifiable information.121
To the extent they do not receive federal funds for research, companies like 23andMe are not covered by the Common Rule. If they
intend to bring a product to market, however, PGT companies may be
subject to the Food and Drug Administration (FDA) human subject
protection requirements, which are similar to those enumerated in the
Common Rule.122 FDA regulations govern clinical studies submitted
in marketing applications for new drugs and biological products and
marketing applications and reclassification petitions for medical devices. Under FDA rules, there are eight basic elements of informed
consent, including an explanation of the purposes of the research and
the expected duration of participation, a description of the procedures
to be followed, identification of any experimental procedures, a de-

clinical trial and future research use of patient data and human tissue. Id. at 40,892.
Under the proposed rule, HIPAA-covered entities could combine both conditioned
and unconditioned authorizations, as long as the document clearly states that the
individual may opt in to the unconditioned research activities. Id. The second provision would modify the HHS rule that authorization for future use of protected health
information in research be study-specific. Id. at 40,893, 40,894. Moreover, in order
to remain consistent with the Common Rule, SACHRP and the Institute of Medicine
(IOM) have both recommended that HHS allow researchers to seek consent for future
research if there is enough description of possible future uses in the document to
allow for informed consent. Medical Research Law & Policy Report, HIPAA Proposes Rule Change to Streamline Informed Consent, Authorization for Research, 9
MRLR 441 (July 21, 2010).
121
See Human Subjects Research Projections: Enhancing Protections for
Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76
Fed. Reg. at 44,525. The ANPRM recognizes that advances in “genetic and information technolog[y] [have made] complete de-identification of biospecimens impossible
and re-identification of sensitive health data easier.” See also Narayanan & Shmatikov, supra note 118, at 26 (“Unfortunately, advances in the art and science of reidentification, increasing economic incentives for potential attackers, and ready availability of personal information about millions of people (for example, in online social
networks) are rapidly rendering [de-identification] obsolete.”). However, SACHRP
does not endorse the assertion that biospecimens are inherently identifiable. Letter
from Barbara E. Bierer to the Honorable Kathleen Sebelius, supra note 116 at 53.
122
See 21 C.F.R. §§ 50, 56, 312, 812 (2011); see Comparison of FDA and
HHS Human Subject Protection Regulations, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/Education
alMaterials/ucm112910.htm (last updated Mar. 10, 2009).
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scription of foreseeable risk, appropriate alternative procedures or
courses of treatment, and a statement of voluntariness.123
For example, the recruitment of research participants on social
networking sites such as PatientsLikeMe, like in the case of Novartis’
2008 study for a multiple sclerosis drug, would be subject to FDA
regulations.124 The FDA considers direct advertising for study participants to be the start of the informed consent and recruitment/enrollment process, explaining that “[a]dvertisements should be
reviewed and approved by the IRB as part of the package for initial
review.”125 As noted above, however, in the studies proposed by
companies like 23andMe, individuals may have been recruited, and
have agreed to participate in hypothetical research, without any prior
knowledge of how their genetic and phenotypic information will be
used or who will be doing the research. Thus, they may already be
“participating” in research (having submitted a biological sample and
disclosed personal information and family history) before a protocol
has been put in place. In those cases, there is no one to screen potential participants, no one responsible for the informed consent process,
and personal data could presumably be used repeatedly in a number of
different studies and scenarios.
Moreover, certain studies may not be subject to FDA oversight, as
the agency’s authority only covers trials relied upon to determine and
establish a product’s safety and efficacy126—not, for example, studies
necessary for obtaining patent protections, Phase IV trials, or generally, where the company and/or sponsor are seeking to identify genetic predispositions to traits or illnesses but are not seeking to create
123

21 C.F.R. § 50.25.
A Safety and Efficacy Study of ELND002 in Patients with Relapsing Forms
of
Multiple
Sclerosis,
PATIENTSLIKEME,
http://www.patientslikeme.com/clinical_trials/NCT01144351-MS-SPMS-RRMSRelapsing-Forms-of-Secondary-Progressive-Multiple-Sclerosis-SPMS-or-RelapsingRemitting-Multiple-Sclerosis-RRMS (last visited Sept. 17, 2009).
125
Recruiting Study Subjects—Information Sheet, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/RegulatoryInformation/Guidances/ucm126428.htm (last
updated Oct. 18, 2010). FDA guidance makes clear that direct online advertising for
potential clinical research participants is not per se objectionable: “IRB review and
approval of listings of clinical trials on the internet would provide no additional safeguard and is not required when the system format limits the information provided to
basic trial information, such as: the title; purpose of the study; protocol summary;
basic eligibility criteria; study site location(s); and how to contact the site for further
information. Examples of clinical trial listing services that do not require prospective
IRB approval include the National Cancer Institute’s cancer clinical trial listing
(PDQ) and the government-sponsored AIDS Clinical Trials Information Service
(ACTIS).” Id.
126
Id. § 54.2(e).
124
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a drug or device that would require FDA approval.127 Such gaps in
the regulatory scheme are troubling.128
There is little relevant case law regarding informed consent and
the donation of genetic data for research. It might be argued that
sponsors of research have a duty to disclose the possibility that a customer’s genetic information will be used for various and unpredictable
research purposes which would lead to the inurement of the company.
However, a federal district court declined to extend the duty of informed consent to cover disclosure of an investigator’s financial interests in studies in which the participants’ biological samples were
used.129
B.

Ensuring Informed Consent in Social NetworkingBased Genetic Research

In light of diverging and incomplete regulations, there is obvious
disagreement regarding the method and structure of informed consent
for genome-wide research, particularly research that originates from
data collected via social networking by PGT companies. As noted
above, the investigators, nature, purpose, and methods of future research may not be known or identified at the time samples are collected.130 Even assuming that it is enough that participants sign an
informed consent document, the issue of how far the consent can and
should go still exists. To what may participants consent? Can they
consent solely to research related to a specific illness? If so, should
there be an opt-out option for certain types of research? Can participants give blanket consent covering all research utilizing their personal and genetic information? Or must participants be approached
each time a new study is initiated? Empirical research suggests that,
when participating in genetic studies, many people want to be asked to
127

See U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-06-402, DRUG SAFETY:
IMPROVEMENT NEEDED IN FDA’S POSTMARKET DECISION-MAKING AND OVERSIGHT
PROCESS 6 (2006), available at http://www.gao.gov/new.items/d06402.pdf.
128
See Letter from Barbara E. Bierer to the Honorable Kathleen Sebelius,
supra note 116 at 36 (providing a useful list of areas and types of research that are not
currently subject to federal regulations that protect participants of research).
129
Greenberg v. Miami Children’s Hosp. Research Inst., 264 F. Supp. 2d
1064, 1070 (S.D. Fla. 2003) (tissue and fluid donors accused the physicianinvestigator of failing to inform the donors that the hospital stood to benefit financially from the research on Caravan disease).
130
See id. at 1069. For a thorough review of proposals for informed consent
in data collection in biobanking, see also Elena Slavaterra et al., Banking Together: A
Unified Model of Informed Consent for Biobanking, 9 EMBO REP. 307, 307-10
(2008).
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be enrolled for each study or type of study.131 However, re-contacting
a large number of sample donors for consent may be impractical or
even impossible.132
Commentators have noted the divergent informed consent practices in the United States for research conducted on biological samples.133 Research reveals evidence that IRBs vary in their consent
form requirements for genetic research.134 A survey of thirty studies
involving biospecimens determined that one-time general consent,
with the requirement that an ethics committee reviews and approves
future projects, is the “best option,” as it reflects the preference of
most individuals.135 Research has also demonstrated that potential
participants would prefer a prospective opt-in consent approach,
rather than an opt-out process.136 Additionally, due to concerns about
genomic privacy for those participating in research, commentators
have advocated an open-consent framework.137 At the very least, the

131
Darren Shickle, The Consent Problem with DNA Biobanks, 37 STUD. HIST.
& PHIL. BIOLOGICAL & BIOMEDICAL SCI. 503, 513 (2006).
132
See Paul S. Appelbaum, Professor, Columbia Univ., Informed Consent:
Recent Developments in Legal and Ethical Requirements for Data Collection and
Use,
available
at
http://www7.nationalacademies.org/cpop/Appelbaum%20Presentation.pdf (last visited Sept. 17, 2009) (citing Shickle, supra note 131).
133
Leslie E. Wolf & Bernard Lo, Untapped Potential: IRB Guidance for the
Ethical Research Use of Stored Biological Samples, IRB: ETHICS & HUM. RES., JulyAug. 2004, at 1, 1-2.
134
See Mary T. White & Jennifer Gamm, Informed Consent for Research on
Stored Blood and Tissue Samples: A Survey of Institutional Review Board Practices,
9 ACCOUNTABILITY RES. 1 (2002). The authors found greater attention to human
subjects protection corresponding to the location of the IRB, the number of protocols
evaluated each year, whether the IRB included a member with ethical expertise in
genetics, and whether the IRB used both the IRB Guidebook and the National Bioethics Advisory Commission (NBAC) Report on Research Involving Human Biological
Materials in its deliberations. Id. at 2, 13-15.
135
Wendler, supra note 103, at 546. The author notes that although one-time
general consent “does not allow people to control the projects for which their samples
are used, there is no reason to think that they want to make such decisions.” Id. The
author recommends six specific elements for the consent form and process: “request
to obtain samples for future research; risks, if any; absence of direct benefits; information, if any, to be provided by individuals; reliance on ethics committees to review
and approve future research provided it finds the research is ethical and poses no
greater than minimal risk; and solicitation of individual questions.” Id. at 546-47.
See also Simon, supra note 108, at 826 (finding that, in consenting to future research,
participants prefer broad, research-unspecific consent over categorical and study
specific consent models).
136
Simon, supra note 108, at 826.
137
See, e.g., Jeantine E. Lunshof et al., From Genetic Privacy to Open Consent, 9 NATURE REV. GENETICS 406, 409 (2008).
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consent process, including consent forms, should address the possibility of data sharing.138
There is little evidence that PGT companies have devoted adequate time or energy to concerns regarding informed consent, and
PGT companies seeking to collect and use individuals’ genetic and
phenotypic data have been reluctant to explicitly describe how consent to research would be ensured in all cases. Most of these companies’ policies focus on the implications of testing and participating in
the recreational aspects of their products, without considering, separately and thoroughly, the need for an informed consent process for
research conducted as a result of an individual’s participation in their
services. In fact, it has been noted that the information provided in
the PGT companies’ documents “focus[es] on privacy protections, the
corporate intent to give information but no diagnosis or health assessment, and the fact that data sharing is the responsibility of the
individual,” rather than focusing on the risks associated with the collection of data or the types of studies to be undertaken.139 For example, users of deCODE Genetics’ products are not required to sign a
consent form, but are informed on the website that the “deCODEme
genetic scan is for informational purposes only; it is not a medical
test, and it is by no means a substitute for professional medical advice,
genetic counseling, diagnosis, or treatment.”140 23andMe does address informed consent for research,141 albeit deficiently, by requiring
that prior to having their sample processed, users must read and acknowledge an online “Consent and Legal Agreement” which discloses
some, but not all, elements of informed consent (e.g., although it
states that the company may enter into partnerships with both forprofit and nonprofit organizations for the purpose of scientific research, it does not provide a description of the research).142 The Per138

See Susan Wallace et al., Consent and Population Genomics: The Creation of Generic Tools, IRB: ETHICS & HUMAN RES., Mar. 2009, at 15, 16.
139
Karin Esposito & Kenneth Goodman, Genethics 2.0: Phenotypes, Genotypes, and the Challenge of Databases Generated by Personal Genome Testing, AM.
J. BIOETHICS, July 2009, at 19, 20.
140
Frequently Asked Questions, DECODEME, http://www.decodeme.com/faq
(last visited Apr. 12, 2011).
141
According to 23andMe, customers must agree to be involved in its
23andMe Research initiative. The “Consent and Legal Agreement” states that
23andMe will only provide individual level data to external researchers upon individual consent from each customer. Consent Document, supra note 59. In fact, a bill
introduced in California, supported by 23andMe, would (among other things) require
companies to obtain informed consent before using individuals’ de-identified genetic
data for research purposes. S.B 482, 2009-10 Reg. Sess. (Cal. 2009).
142
Consent Document, supra note 59. Shortly before publication, 23andMe
revised its privacy statement, with the support of a privacy-verifying consultant,
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sonal Genome Project’s two-step informed consent process involves
detailed informed consent documents which are periodically updated;
they include contact information for the primary investigator and others and more closely represent the framework for informed consent
envisioned by the Common Rule.143 Prospective participants must
read, review, and electronically sign two different consent forms: (1) a
“mini-consent” for eligibility screening procedures; and (2) the full
consent for enrollment and ongoing participation.144
Even if PGT companies’ forms and online policies made comprehensive disclosures as to the consequences of participation in research, the companies’ approaches to informed consent would still be
insufficient. Informed consent is best understood as a process, rather
than a one-time occurrence where a simple form is read and signed,
that obligates investigators to ensure that potential research participants appreciate and understand the risks, benefits, and alternatives to
participating in research. Because informed consent often requires a
meeting with a medical provider or someone involved in the research
to explain the risks and implications of participation and answer ques-

TrustE.
Privacy
Highlights
Page,
23ANDME,
https://www.23andme.com/legal/privacy/ (last visited Dec. 9, 2011); Summary of
Changes
to
the
23andMe
Privacy
Statement,
23ANDME,
https://www.23andme.com/you/faqwin/privacychanges/ (last visited Dec. 9, 2011).
Of the substantive changes to the general privacy policy—as it applies to the collection and handling of personal information for recreational purposes, site use statistics,
and customer testimonials—the company added one provision related to research,
which allows third-party research consultants to do on-site research at 23andMe facilities, utilizing data from participants who have consented to 23andWe Research.
See also Kashmir Hill, Privacy Policy Changes Should be Crystal Clear, Especially
When Your Genes are Involved, FORBES.COM (Dec. 7, 2011, 12:05 PM),
http://www.forbes.com/sites/kashmirhill/2011/12/07/privacy-policy-changes-shouldbe-crystal-clear-especially-when-your-genetic-info-is-involved/.
143
Current
Consent
Forms,
PERSONAL
GENOME
PROJECT,
http://www.personalgenomes.org/consent/ (last visited Oct. 23, 2011).
144
Participation
Overview,
PERSONAL
GENOME
PROJECT,
http://www.personalgenomes.org/participate.html (last updated Mar. 3, 2011); see
GENOME
PROJECT,
also
Mini
Consent
Form,
PERSONAL
http://www.personalgenomes.org/consent/PGP_MiniConsent_Approved_02222011.p
df (last visited Oct. 23, 2011). The mini consent form discloses a principal investigator, and describes the purpose broadly, “to explore ways to connect human genetic
information with human trait information (i.e., human DNA sequence, medical information, tissue samples and physical traits) so that such data may be used for hypothesis-generating research and other scientific, clinical and commercial development
efforts worldwide.” Id. Cf. Full Consent Form, PERSONAL GENOME PROJECT,
http://www.personalgenomes.org/consent/PGP_Consent_Approved_02222011.pdf
(last visited Oct. 23, 2011).
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tions,145 only requiring participants to sign an online consent form
before contributing to research may not be enough to meet the elements of the FDA regulations or the Common Rule. Most companies
have not identified if and how they intend to follow up with participants (although TruGenetics has stated its intent to eventually share its
discoveries),146 how participants can ask questions or express concerns during the course of a study, or whether or when participants
may withdraw from the research if they change their mind. Further
consideration is needed to determine how best to disclose risks and
benefits to customers so that they understand the implications and
breadth of potential participation in research.
C.

IRB Oversight of Social Networking-Based
Research: An “Unfortunate Loophole”

Where studies are subject to FDA regulations and the Common
Rule, they must be approved by an IRB to assure that appropriate
steps are taken to protect the rights and welfare of participants. However, many of the PGT companies have not publically identified an
IRB for approval of their research protocols. Nor may companies be
eager for IRB oversight; a bill supported by 23andMe that was introduced in the California legislature in April 2009 would explicitly not
require companies to obtain IRB approval before conducting research
using genetic data.147 In cases where there is no IRB to oversee the
informed consent process, there is little guarantee that research participants’ rights will be protected.
In March 2009, OHRP released its GINA Guidance148 to clarify
how GINA will affect genetic research that is conducted or supported

145

Institutional Review Boards Frequently Asked Questions — Information
&
DRUG
ADMIN.,
Sheet,
U.S.
FOOD
http://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm (last updated
Aug. 9, 2011) (“The entire informed consent process involves giving a subject adequate information concerning the study, providing adequate opportunity for the subject to consider all options, responding to the subject’s questions, ensuring that the
subject has comprehended this information, obtaining the subject’s voluntary agreement to participate and, continuing to provide information as the subject or situation
requires.”).
146
TruGenetics Terms & Conditions, supra note 19.
147
See S.B 482, 2009-10 Reg. Sess. (Cal. 2009).
148
GINA prohibits discrimination in health coverage and employment based
on genetic information, with implications for disclosure and informed consent. Office
for Human Research Prot., Guidance on the Genetic Information Nondiscrimination
Act: Implications for Investigators and Institutional Review Boards, DEP’T HEALTH &
HUMAN SERVS. 1-2 (Mar. 24, 2009), http://www.hhs.gov/ohrp/policy/gina.pdf. GINA
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by HHS.149 The Guidance provides nonbinding recommendations to
researchers, emphasizing that investigators and IRBs should disclose
reasonably foreseeable risks related to genetic research and not overstate the protections provided by GINA.150 Investigators and IRBs
must continue to vigilantly monitor how risks are described for genetic research, because GINA does not apply to life insurance, disability insurance, and long-term care insurance. For these types of insurance, providers may deny coverage or increase premiums based on
known genetic predispositions. The Guidance recommends specific
language for investigators and IRBs to include in informed consent
documents. Further, the Guidance recommends that IRBs overseeing
genetic research should also consider the provisions of GINA when
assessing whether such research satisfies the criteria required for approval, keeping in mind that risks to subjects are minimized and reasonable in relation to anticipated benefits, and there are adequate provisions to protect the privacy of subjects and maintain the confidentiality of data.151
When 23andMe sought publication of its GWAS on multiple traits
using self-reported data via the internet, the journal PLoS Genetics
delayed publication to consider the company’s lack of IRB review.152
23andMe asserted that its study was exempted from review because it
was not “human subjects research.” In the same issue in which the
final article appears, the journal’s editors stated that, “[o]n the face of
it, this seems preposterous, but on further review, this decision follows not uncommon practices by most scientists and institutional review boards, both academic and commercial, and is based on a guidance statement from [OHRP].”153 The editors called this an “unfortuwent into effect for health insurance companies in May 2009 and for employers in
November 2009. Id.
149
GINA includes a “research exception” to the prohibition against requesting
that an individual undergo a genetic test, which allows “a group health plan, or a
health insurance issuer offering health insurance coverage in connection with a group
health plan” to “request, but not require, and that a participant or beneficiary undergo
a genetic test if” certain conditions are met. These conditions include that the research comply with the Common Rule, participation is voluntary, that the government
is notified in writing of the research. Genetic Information Nondiscrimination Act of
2008, Pub. L. No. 110-233, §1180, 122 Stat. 881, 904.
150
Office for Human Research Prot., Guidance on the Genetic Information
Nondiscrimination Act: Implications for Investigators and Institutional Review
Boards, DEP’T HEALTH & HUMAN SERVS. 5 (Mar. 24, 2009),
http://www.hhs.gov/ohrp/policy/gina.pdf.
151
Id.
152
Gibson & Copenhaver, supra note 48.
153
Id. (stating the two criteria that qualify research as human subject research:
(1) “will the investigators obtain the data through intervention or interaction with the
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nate loophole.”154 The journal further required that the authors address their concerns about the consent process, and in response,
23andMe has fully engaged a formal IRB. In June 2010, 23andMe
announced that it had received IRB approval for its research protocol
and an accompanying revised consent document for its research intended for publication, although the company explicitly disavowed
being required to do so.155 In its announcement, the statement explained, “[b]ecause the 23andMe protocol excludes individual identifying information (e.g. name, email address, user ID, Password, payment information, etc.) and our analysts do not interact directly with
customers during data collection, our research technically does
not require IRB review.”156
V.

OWNERSHIP/INTELLECTUAL PROPERTY CONCERNS

Some of the policies listed on PGT companies’ websites are ambiguous as to ownership of the biospecimens or data collected for
research.157 For example, formerly, Pathway’s disclosures simply
stated, “[y]our DNA and results belongs to you and no one else.”158
Then, in what might have been a confusing switch for the consumer,
the company asserted that it may use certain information that does not
disclose the customer’s identity to conduct scientific and medical research, in collaboration with nonprofit or commercial organizations.159
participants,” and (2) “will the identity of the subject be readily ascertained by the
investigator or associated with the information.”) (citing Office for Human Research
Prots., Guidance on Research Involving Coded Private Information or Biological
Specimens, DEP’T HEALTH & HUMAN SERVS. 2 (Oct. 16, 2008),
http://www.hhs.gov/ohrp/policy/cdebiol.pdf).
154
Id. at 2.
155
23andMe Improves Research Consent Process, THE SPITTOON (June 24,
2010), http://spittoon.23andme.com/2010/06/24/23andme-improves-research-consentprocess/.
156
Id. (alteration in original).
157
The PGP, which has a different focus than the for-profit DTC genetic
testing companies, clearly states, “[n]either you nor your heirs will gain financially
from any discoveries, whether or not of a commercial nature, made using the information that you provide.” Mini Consent Form, supra note 144.
158
Pascal Borry et al., Preconceptional Genetic Carrier Testing: Direct-toConsumers: The Appropriate Use of Existing Resources, 26 HUM. REPROD. 972, 975
(2011) (linking readers to a since-modified website, DNA Security, PATHWAY
GENOMICS,
http://web.archive.org/web/20100515174056/http://www.pathway.com/more_info/dn
a_security (last visited Sept. 17, 2009) (accessed by searching for the URL on Internet
Archive database)).
159
Privacy
Policy,
PATHWAY
GENOMICS,
http://web.archive.org/web/20090328011950/http://www.pathway.com/more_info/pri
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Generally, institutions have successfully claimed ownership of
biospecimens. In the 1990 case Moore v. Regents of the University of
California, the Supreme Court of California held that a patient with
hairy cell leukemia had a cause of action against his physician based
on a breach of fiduciary duty because the physician failed to disclose
his intent to use portions of the plaintiff’s spleen in research for which
the physician hoped to benefit financially. However, the court even-

vacy_policy (last updated Mar. 20, 2009) (“We may provide your Genetic Information and Survey-Based Information, unlinked from your name and Account Information, to research collaborators to conduct Pathway Genomics-authorized scientific
research and development. You cannot opt-out from this research. We also may pass
on to you a research collaborator’s request that you volunteer additional information
or participate in a study. No name or Account Information is shared with a research
collaborator without your express consent.”) (emphasis added) (accessed by searching
for the URL on Internet Archive database). Later, the policy explained, “Pathway
Genomics believes in furthering responsible scientific and medical research to improve our understanding of genetics and to assist physicians and other health-care
professionals to provide better health care. Collaborations between Pathway Genomics and non-profit or commercial research organizations will be guided by a research
advisory committee established by Pathway Genomics. Any research collaborator will
first need to obtain permission from an appropriate Institutional Review Board.”
GENOMICS,
Privacy
Policy,
PATHWAY
http://web.archive.org/web/20100405082115/http://www.pathway.com/more_info/pri
vacy_policy (last updated Dec. 21, 2009) (accessed by searching for the URL on
Internet Archive database). This policy has subsequently been changed to what they
refer to as an opt-in system, and now reads, “Pathway may want to work with other
entities and organizations to conduct scientific research and other legitimate secondary purposes using the DNA obtained from your specimen. However none of your
personal information will be shared for any secondary purpose outside the immediate
control of Pathway, unless you expressly opt-in to authorize this…. We also may
pass on to you a research collaborator’s request that you volunteer additional information or participate in a study. No name or Account Information is shared with a research collaborator without your express consent and the research collaborator agreeing to comply with all appropriate privacy and information security laws and regulations to protect such personal information.” Privacy Policy, PATHWAY GENOMICS,
https://www.pathway.com/more_info/privacy_policy (last updated Oct. 22, 2010).
Similarly, 23andMe’s privacy policy states, “[i]f you do not give consent for your
Genetic and Self-Reported Information to be used in 23andWe Research, we may still
use your Genetic and/or Self-Reported Information for R&D purposes… which may
include disclosure of Aggregated Genetic and Self-Reported Information to thirdparty non-profit and/or commercial research partners who will not publish that information in a peer-reviewed scientific journal.” Privacy Highlights Page, supra note
142. However, it continues, “[e]xcept as otherwise set forth herein, we will never
release your individual-level Genetic and/or Self-Reported Information to a third
party without asking for and receiving your explicit consent to do so, unless required
by law.” Id.
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tually found that donors do not have an ownership interest in their
cells after the cells have been removed from their bodies.160
In 2008, in Washington University v. Catalona, the Eighth Circuit
upheld the lower court’s decision that tissue and serum samples donated to Washington University could continue to be used by the institution for cancer research, despite the donors’ wishes to transfer ownership of the samples to another research institution. The Court of
Appeals stated that the “pivotal inquiry in this dispute” was “whether
individuals who make an informed decision to contribute their biological materials voluntarily to a particular research institution for the
purpose of medical research retain an ownership interest allowing the
individuals to direct or authorize the transfer of such materials to a
third party.”161 The Court held that “[u]nder the facts of this case, the
answer is no.”162
It is not unprecedented for companies to prevent others from
studying or testing a gene for which they hold a patent. An ongoing
lawsuit against Myriad Genetics has highlighted the controversy surrounding the U.S. Patent & Trademark Office (USPTO)’s permissive
attitude toward gene sequence patents. In March 2010, the Southern
District of New York held that isolated human genes were unpatentable subject matter, and invalidated Myriad’s patent claims relating to
the BRCA1 and BRCA2 genes.163 In July 2011, the Court of Appeals
partially reversed the lower court’s decision, holding that isolated
DNA is patentable because it is markedly different from the DNA as it
exists within the body and is therefore not simply a product of na160

Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 493 (Cal. 1990).
However, Moore has questionable application, because the relationship between the
testing companies and the participants in these cases is not a therapeutic one, and
because these PGT companies disclose to participants that they will not benefit financially. Id. at 483. However, to the extent that PGT companies are not explicit in their
intent, it implicates the court’s belief that Moore’s physician’s behavior was particularly egregious, as he actively misled Moore by telling him that the research team was
“engaged in strictly academic and purely scientific medical research” and “there was
no commercial or financial value to his Blood and Bodily Substances.” Id. at 486.
See also Greenberg v. Miami Children’s Hosp. Research Inst., 264 F. Supp. 2d 1064,
1073 (S.D. Fla. 2003) (tissue and fluid donors alleged that hospital had fraudulently
concealed that it: (1) would economically benefit from the research; (2) would patent
the Canavan gene mutation; and (3) would license the testing under the patent).
161
Wash. Univ. v. Catalona, 490 F.3d 667, 673 (8th Cir. 2007). See also Lori
Andrews, Who Owns Your Body? A Patient’s Perspective on Washington University
v. Catalona, J. L. MED. & ETHICS 398, 298 (2006).
162
Wash. Univ., 409 F.3d at 673.
163
Whether genetic tests and diagnostic tools are patentable is at issue in the
ACLU suit against the PTO and Myriad Genetics for Myriad’s screening tests for the
breast cancer genes, BRCA1 and BRCA2. See Ass’n for Molecular Pathology v.
USPTO, 702 F. Supp. 2d 181, 222 (S.D.N.Y. 2010).
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ture.164 The Court upheld, however, the invalidity of the patent claim
over the analytic process for examining and comparing genes to identify the BRCA mutations because it involved “patent-ineligible abstract[] mental steps.”165 The case is being appealed.
It is foreseeable that contributors of genetic and biological data
might assert a property right in applications or products that arise out
of research. However, patient-driven research does not correlate to
patient-owned results and products. Throughout the process of collecting data, developing diagnostic tools and tests, and designing
treatments, applications, pharmaceuticals, or biologics, a number of
products may become ripe for patenting, licensing, and marketing.166
Based on the fine print found on PGT websites, it is often clear that
the participant/consumer will not financially gain from his or her participation.
Despite claims of democratization and collaboration, both public
and private companies assert that they themselves will retain and exercise the right to any property interest created by the research. These
companies may, however, negotiate ownership and IP rights with their
commercial partners, or deal the rights away to other third parties.
However, recent USPTO actions have indicated that collaborating
in genetic research may constitute inventorship.167 Initiatives such as
the PGP will likely spur nonscientist collaborators to ask the USPTO
to consider granting them joint inventorship. The partnership of social networking and genetic testing projects will certainly lead to a
demand to expand the concept of joint inventorship. Even to the extent that participants do not have a legal right to the intellectual property arising out of research, participants may still expect or seek access to tests developed from the results of their contribution for a discount.

164

Ass’n for Molecular Pathology v. USPTO, 653 F.3d 1329, 1333-34 (Fed.
Cir. 2011).
165
Id. at 1334.
166
For a thorough consideration of the issues related specifically to gene
patenting, an area itself rife with issues, see Lori B. Andrews & Jordan Paradise,
Gene Patents: The Need for Bioethics Scrutiny and Legal Change, 5 YALE J. HEALTH
POL’Y L. & ETHICS 403, 403-04 (2005).
167
See Jordan Paradise, Patient Advocacy Group Collaboration in Genetic
Research and the Scope of Joint Inventorship Under U.S. Patent Law, 3 INT’L J.
INTELL. PROP. MGMT. 97, 100, 104 (2009) (stating that the USPTO named a nonscience advocate as a co-inventor on a patent for a disease gene).
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CONCLUSION
As the story of Lorenzo Odone exemplifies, research driven by
patients’ preferences and needs is not unique to genetic research arising out of social networking. Recent history is rife with individual
initiatives, foundations, and companies dedicated to spurring research
and finding cures. In 2003, the daughter of Hugh Rienhof, the founder of DNA Sciences and an advisor to biotech companies, was born
with undiagnosed congenital defects.168 He had her genes sequenced
and shared information about her conditions and portions of her genetic information on the internet. The founder of PatientsLikeMe
started the online company after his brother, Stephen Heywood, was
diagnosed with Lou Gehrig’s disease (both brothers had previously
founded ALS TDF, a nonprofit biotechnology company and ALS
research center). Stephen spent the last three years of his life on an
experimental drug developed by ALS TDF.169
Initiatives such as the PGP are poised to compete with efforts by
for-profit companies such as 23andMe.170 Such competition is remi168

Brandan Maher, Personal Genomics: His Daughter’s DNA, 449 NATURE
772, 773 (2007).
169
Stephen Heywood, 37, Dies; Master-Builder/Architect Subject of the 2006
Major Motion Picture So Much So Fast, PATIENTSLIKEME (Nov. 30, 2006),
http://www.patientslikeme.com/press/20061130/1-stephen-heywood-37-diesmasterbuilder-architect-subject-of-the-2006-major-motion-picture-so-much-sofast?disease_tag=hiv.
170
The PGP is by no means the only non-profit initiative focused on using
genomics and social networking to identify diseases and pursue treatments. The Rare
Genomics Institute (RGI)’s initiative is perhaps the most patient-driven of its kind.
RGI, a nonprofit organization founded in 2011 that aims to “empower[] patient communities to accelerate research by helping fund and creating personalized research
projects based on individuals with rare diseases,” provides three interrelated services:
(1) a “micro-funding website,” an “online fundraising platform and social network
that helps patient community raise funds”; (2) a researcher network, which provides
access to genomics researchers who will sequence and analyze the patients’ information; and (3) a clinical network, which connects “patients with clinicians and genetic
counselors who will help interpret and translate the individualized research findings.”
About Us, THE RARE GENOMICS INSTITUTE, http://www.raregenomics.org/about.php
(last visited Oct. 26, 2011). Thus, a patient diagnosed with a rare disease that is considered a good candidate for sequencing-based research is invited to create an online
profile, tell his or her story, and upload pictures in an effort to raise funds to support
RARE
GENOMICS
INSTITUTE,
the
research.
For
Patients,
THE
http://www.raregenomics.org/patients.php (last visited Oct. 26, 2011). RGI will then
coordinate the use of these community-raised funds and anonymized rare disease
patient genomes in research. Researchers who conduct research utilizing data provided by RGI may publish results, together with the organization. By using a crowdfunding approach to raise money for whole genome sequencing and analysis in children with rare or orphan genetic diseases, the organization hopes to contribute to a
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niscent of the “race” between Craig Venter and the Human Genome
Project (HGP), where privately-funded researchers (who are subject to
different and, often less, regulation) forced a publicly-funded institution to compete, resulting in increased effectiveness and productivity
on both sides.171 In an ideal world, the contest to recruit volunteers to
contribute genetic and other personal information would encourage
research and competition to create diagnostics and treatments that will
benefit society.172
better understanding of diseases and the development of new treatments. Currently,
the organization’s website does not contain any information regarding privacy or
consent, but does state that “RGI will ensure that patient information is kept in the
strictest confidence according to government regulations.” It continues, “[s]equences
will only be made available to the research community once they have been completely anonymized.” For Patients, THE RARE GENOMICS INSTITUTE,
http://www.raregenomics.org/patients.php (last visited Oct. 26, 2011). Further, RGI’s
website contains the following disclaimer: “[a]ll the genome sequencing projects are
for research informational purposes only and are subject to change. No medical medical [sic] advice, diagnosis or treatment are provided.” For Donors, THE RARE
GENOMICS INSTITUTE, http://www.raregenomics.org/donors.php (last visited Oct. 26,
2011).
171
See Getting Personal: The Promise of Cheap Genome Sequencing,
ECONOMIST, Apr. 18, 2009, at 9, 10. The HGP sequenced the genome for $4 billion,
while Venter did it for $100 million. Id. at 10.
172
In a novel approach to genetic research and social networking, openSNP, a
non-profit, open-source project founded in September 2011, seeks to allow customers
of direct-to-customer genetic tests—currently, deCODE Genetics and 23andMe—to
publish their raw data test results and phenotypes, characteristics, and traits, find
others with similar genetic variations, and search primary literature on their variations
and “help scientists to find new associations.” OPENSNP, http://opensnp.org/ (last
visited Oct. 28, 2011). Participants make their full genotypic raw data available online, which may be accessed via a mass download-function “to enable everybody
to perform crowd-sourced association studies,” thereby “making science more open
and accessible.” For Scientists, OPENSNP, http://opensnp.org/ (last visited Oct. 28,
2011); About, OPENSNP, http://opensnp.wordpress.com/about (last visited Oct. 28,
2011); 5 Days After Launch—Time for Some More Information, OPENSNP (Oct. 3,
2011),
http://opensnp.wordpress.com/2011/10/03/5-days-after-launch%E2%80%93%C2%A0time-for-some-more-information/.
Future features to be
added include social media efforts and support for Family Tree DNA, another service
that provides DTC-testing. The organization describes 23andMe’s policy of not
sharing its datasets with other researchers outside of 23andMe and their collaborators,
and explains its decision to make such information public: “[w]hile there may be
many valid reasons not to publish those datasets, we feel that research projects all
over the world and science in general would benefit from such a rich source of linked,
genetic data that is freely available.” Welcome to openSNP, OPENSNP (Sept. 26,
2011), http://opensnp.wordpress.com/2011/09/26/welcome-to-opensnp/. openSNP’s
“disclaimer” describes the “possible risks and side-effects that can occur by making…
genetical and medical information available on this platform,” including challenges to
privacy (“[a]lthough you can upload your data using a pseudonym, there is no way to
anonymously submit data”), confidentiality, and the potential for genetic discrimination. Disclaimer, OPENSNP, http://opensnp.org/disclaimer (last visited Oct. 28, 2011).
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However, PGT companies that utilize online social networking
technologies are ushering in a new model for human subjects research, one which our current laws, regulations, institutions, and IRBs
may not be prepared to handle. PGT companies, despite good intentions, may not be in the best position to protect the needs, desires, and
rights of customers who choose to participate in research initiatives.
These companies often blur the line between the recreational and the
clinical, and individuals may not be fully informed of the risks and
benefits of participating in research advanced by PGT companies. In
fact, one of the most challenging aspects of the hybrid of PGT and
social networking is the fact that customers may become research
participants without full knowledge or understanding of the transformation of their roles. In order to ensure the appropriate use of PGT
sites for recruiting purposes, transparency in partnerships between
pharmaceutical companies and PGT providers is necessary, so that
users understand the nature of the relationships and how they fit in.
A greater focus on regulation of the PGT/social networking hybrid model for research is essential. A deliberate evaluation of the
application of existing laws and a consideration of new ones is needed
in order to find a balance between efficient research using personal
and genetic information with the long-term interests and values of
individuals. Our first approach should be a reconsideration of how
our current consent model applies to social networking-based genetic
research. Recent publications of GWAS by PGT companies have
intensified the need for a consistent and standardized informed consent process. Obtaining more adequate, honest, and complete consent
from participants would be most effective at the time of initial contribution of information, although in some circumstances, re-consent
may be required. Further, clarifying (and if necessary, extending,
regardless of funding source) the reach of the Common Rule to
crowd-sourced genetic research would help to ensure the protection of
all participants.

